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Introduccio´n
En este trabajo se persiguen dos objetivos generales:
a) El estudio de disen˜os experimentales adaptados a la respuesta y la propuesta de un
nuevo disen˜o competitivo en propiedades tanto e´ticas como inferenciales respecto a los ya
existentes.
b) El ana´lisis de la inferencia basada en la aleatorizacio´n en el marco de disen˜os adap-
tados a la respuesta.
Las herramientas utilizadas en este trabajo son fundamentalmente probabil´ısticas, ca-
denas de Markov en tiempo discreto tanto homoge´neas como no homoge´neas, teor´ıa de
martingalas y leyes l´ımite de procesos. Tambie´n se han utilizado te´cnicas de inferencia
parame´trica y no parame´trica.
Los disen˜os estad´ısticos en los que se centra esta tesis son los ensayos cl´ınicos. Un
ensayo cl´ınico es, en su versio´n ma´s habitual, un disen˜o que consiste en comparar el
comportamiento de dos tratamientos (dos fa´rmacos o dos protocolos de actuacio´n ante
una enfermedad) con objeto de establecer la superioridad de uno de ellos respecto al
otro. Los ensayos cl´ınicos se diferencian de la mayor´ıa de disen˜os de experimentos por dos
razones principales. Por un lado, las unidades experimentales son los pacientes, con lo
que el experimento adquiere un componente e´tico que no es propio de otros experimentos
estad´ısticos. Este hecho implica una fuerte regulacio´n y control del ensayo por parte de las
autoridades competentes. Por otro lado, la llegada de los pacientes puede ser secuencial,
pudiendo pasar periodos importantes de tiempo entre las diferentes llegadas. Debido a
esta llegada secuencial, la informacio´n se va acumulando y esta´ disponible mientras se
lleva a cabo el experimento. Parece entonces natural el uso de esta informacio´n para
introducir alguna mejora en el experimento. Ante la llegada de un paciente, este es
asignado a uno de los dos tratamientos mediante una regla de asignacio´n aleatoria que
utiliza la informacio´n pasada del ensayo. Estos ensayos se denominan ensayos cl´ınicos
adaptativos. Si la asignacio´n se hace utilizando las asignaciones pasadas junto con las
i
respuestas pasadas, el disen˜o se denomina adaptado a la respuesta. El trabajo se centra
en este tipo de disen˜os, siendo el nu´cleo de esta tesis la presentacio´n y estudio de diversos
aspectos de un disen˜o de ensayo cl´ınico adaptado a la respuesta de fase III, llamado disen˜o
de urna de Klein.
En el cap´ıtulo 1 se hace una presentacio´n del tema de la tesis as´ı como una revisio´n
bibliogra´fica de los tres temas principales que se trabajan en ella, los disen˜os adaptativos,
con especial e´nfasis en los disen˜os adaptados a la respuesta, la inferencia basada en la
aleatorizacio´n y el uso de covariables en disen˜os adaptativos. En el cap´ıtulo 2 se presentan
tres disen˜os adaptados a la respuesta diferentes, basados en el disen˜o de urna de Ehrenfest,
para despue´s efectuar un ana´lisis de sus propiedades y elegir uno para un estudio ma´s
profundo, debido a sus prometedoras propiedades. Este disen˜o se llamara´ disen˜o de urna
de Klein, debido a que se basa en un proceso de urna ya estudiado por Martin J. Klein
dentro del campo de la f´ısica. En este mismo cap´ıtulo se hace un estudio exacto y asinto´tico
del los procesos estoca´sticos asociados al disen˜o, as´ı como un ana´lisis de propiedades ma´s
concretas de los ensayos cl´ınicos, como sesgo de seleccio´n, sesgo accidental o un estudio de
potencia y de las propiedades e´ticas del disen˜o.
Los cap´ıtulos 3 y 4 se dedican a la inferencia basada en la aleatorizacio´n. Debido a
la particularidad del proceso de seleccio´n de pacientes de un ensayo cl´ınico, en el que la
obtencio´n de la muestra de pacientes depende de diversos factores dif´ıcilmente controlables,
la asuncio´n de un modelo poblacional puede ser puesta en duda, con lo que se opta por
asumir un modelo de aleatorizacio´n. En este marco de trabajo inferencial, las respuestas
de los pacientes se consideran fijas y no se asume ningu´n modelo probabil´ıstico para ellas.
Por tanto, la aleatoriedad solo descansa en el proceso de asignacio´n de pacientes, llamado
aleatorizacio´n, y que da base a la inferencia. Bajo este modelo, se presenta un estad´ıstico
de test lineal de rangos para respuestas dicoto´micas. En el cap´ıtulo 3 se obtiene un
algoritmo recursivo que permite el ca´lculo de la distribucio´n exacta del estad´ıstico y que
hace factible el ca´lculo de los p-valores en un tiempo razonable. Este algoritmo es va´lido
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para una amplia gama de disen˜os adaptados a la respuesta en la que esta´ incluido el disen˜o
de urna de Klein. Asimismo, el algoritmo es adaptado para un conocido disen˜o que no
pertenece a esta familia. Utilizando el algoritmo, se completa un estudio de simulacio´n
para la potencia del test con diferentes disen˜os y estad´ısticos. El cap´ıtulo 4 se centra en el
estudio asinto´tico del estad´ıstico para la inferencia basada en la aleatorizacio´n con el disen˜o
de urna de Klein. Las propiedades probabil´ısticas de la urna de Klein bajo este marco
de trabajo cambian sustancialmente, con lo que muchas de las propiedades analizadas en
el cap´ıtulo 2 necesitan ser adaptadas. Utilizando estas nuevas propiedades se obtiene la
distribucio´n asinto´tica del estad´ıstico del test.
Por u´ltimo, en el cap´ıtulo 5 se introducen las covariables en los disen˜os adaptados a
la respuesta, particularmente con el disen˜o de urna de Klein. Se presenta una versio´n
estratificada de dicho disen˜o, analizando las convergencias de los procesos y estimadores
ba´sicos. Por otro lado, se propone la utilizacio´n de un modelo lineal generalizado para de-
terminar la relacio´n de la respuesta con los tratamientos y covariables. Por la dependencia
de los errores de los disen˜os adaptados, la teor´ıa cla´sica, basada en la incorrelacio´n de los
errores, no es aplicable, con lo que es necesario demostrar una ley fuerte y un teorema
central para los estimadores de ma´xima cuasi-verosimilitud. Finalmente, se realiza un
estudio de simulacio´n comparando la inferencia basada en aleatorizacio´n con la inferencia
parame´trica utilizando un modelo lineal generalizado.
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Introduction
This thesis has two general goals:
a) The study of experimental response-adaptive designs and the proposal of a new
design, with good ethical and inferential properties and that it is competitive with respect
to the existing ones.
b) The analysis of randomization based inference for response-adaptive designs.
In this thesis, the main tools are probabilistic, as time-homogeneous and non-homogeneous
Markov chains, martingale theory and limit laws. Some concepts about nonparametric and
parametric inference have also been used.
This dissertation is focused on clinical trials. Commonly, a clinical trial is a statistical
design to compare the behavior of two treatments (two drugs or two intervention protocols)
in order to establish the superiority of one with respect to the other. Two main aspects
distinguish clinical trials from the majority of experimental designs. On the one hand,
the experimental units are patients, so the experiment is concerned about ethics, and this
does not happen in other statistical experiments. This fact implies a strong regulation
and control of the trial by the law and the relevant authorities. On the other hand, the
arrival of the patients can be sequential with long enough interarrival times. Therefore,
the information is accrued and it is available during the experiment. Then, it seems
natural to use this information in order to improve the properties of the design. When
a patient arrives, he or she is assigned to a treatment via a random allocation rule that
takes into account the past information. These designs are called adaptive designs. When
the allocation is made using the past allocations and past responses of the patients, it is
called response-adaptive. This work is focused on these designs and the core of the thesis
is the presentation and study of different features of a response-adaptive phase III clinical
trial design, which is called Klein urn design.
In Chapter 1 the state of the art is reviewed, focusing on the three main addressed
topics, which are: adaptive designs, particularly response-adaptive designs, randomization
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based inference and the use of covariates in response-adaptive designs. In Chapter 2 three
response-adaptive designs are presented, based on the Ehrenfest urn design. After doing an
analysis of their properties, the one with the best properties is chosen for a thorough study.
This design is named Klein urn design, since it was studied as an urn process by Martin J.
Klein in the field of physics. An exact and asymptotic study of some stochastic processes
related to the design are also completed in this chapter. Finally, some characteristic
properties of clinical trials are analyzed when the Klein urn design is used to allocate
patients, as selection bias, accidental bias, power study with parametric inference and
ethical properties of the design.
Chapter 3 and Chapter 4 are focused on randomization based inference. In a clinical
trial, the sampling process differs from the random sampling and the assumption of a
population model is in doubt, so a randomization model is assumed. In this inferential
framework, the patients’ responses are treated as deterministic and no probabilistic model
is assumed for them. Then, the only randomness is due to the random allocation of
patients, called randomization. Under this model, a linear rank statistic for dichotomous
responses is presented. In Chapter 3, a recursive algorithm is obtained to compute the
exact distribution of the test statistic. This algorithm makes feasible the computation of
the p-values and is valid for a wide family of response-adaptive designs, where the Klein
urn design is included. Moreover, the algorithm is adapted also for a well-known design out
of this family. With this algorithm, a simulation study is completed for the power of the
test using different test statistics. In Chapter 4, an asymptotic study of a test statistic for
randomization based inference is made when randomization is made with the Klein urn.
The stochastic properties of the Klein urn change substantially so the properties analyzed
in Chapter 2 must be revisited. Using these new properties, the asymptotic distribution
of the test statistic is obtained.
Finally, in Chapter 5, the introduction of covariates in response-adaptive designs, spe-
cially in the Klein urn design, is studied. A stratified version of the Klein urn design is
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presented and the convergence of the basic processes and estimators is proven. Besides this,
a generalized linear model is used to determine the relation of the responses with the allo-
cations and covariates. Due to the dependence relations generated when adaptive designs
are used, the theory based on incorrelation of the error terms cannot be applied. Then, the
consistency and asymptotic normality of the quasi maximum likelihood estimators must
be proven. To conclude, a simulation study is carried out comparing randomization based
inference and parametric inference using a generalized linear model.
vii
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Chapter 1
Background and literature review
A clinical trial is an experiment performed on human beings in order to evaluate the
superiority of the treatment under study against another treatment or a placebo. A
standard trial has different phases with different goals. In phase I, the potential toxicity
of the new treatment is measured. Phase II studies the effectiveness of different doses. In
phase III a comparison study is done to determine the superiority of the new treatment and
finally, in phase IV a follow-up of the patients is done, see [58] for a detailed explanation.
The particular structure of the experiment makes clinical trials quite different from the
usual statistical experiments, leading to a complicate but challenging statistical design
and analysis. We are going to focus on phase III.
The general framework in this thesis is a design with two treatments, say 1 and 2,
with immediate and binary responses. We assume that patients arrive sequentially to the
experiment. When a patient arrives, he or she is assigned with a randomized allocation rule
to a treatment. The corresponding treatment is applied and the response of the patient,
success or failure, is observed. Let δn be the indicator random variable of treatment 1
assignment; δn = 1 if the treatment 1 is applied to the n-th patient and δn = 0 otherwise.
The indicator of treatment 2 assignment is 1−δn. Nn,1 =
∑n
i=1 δi is the number of patients
assigned to treatment 1 up to the n-th patient. Let Zn = (Zn,1, Zn,2) be the vector of
potential responses of the n-th patient, considering that, for each n, only one is observed.
1
2Unless otherwise stated, we assume the following parametric model. Zn,1 and Zn,2 are
binary variables, taking value 1 with probability p1 and p2, respectively, if the response
of the patient is a success, and being 0 with probability q1 = 1 − p1 and q2 = 1 − p2,
respectively, if the response of the patient is a failure.
1.1 Adaptive Randomization
One of the main advances in the design of clinical trials has been the use of the information
that the experiment is giving in order to achieve several specific or global goals. These
designs are called adaptive designs. When the accrued information is used to perform
treatment allocations, we have an adaptive allocation rule. Depending on the previous
information that we use to allocate the next patient, several kinds of adaptive allocation
rules can be distinguished. Following the approach in [13], when the previous patient
allocations are used to make the next allocation, we are in a treatment-adaptive design.
If the responses of the patients are also included in the past information, the rule is called
response-adaptive. Some covariates, that carry additional information about the patient,
as gender or age, can be taken into account in the allocation rule for each patient n. This
information will be denoted Hn. If we use the covariate information of the past patients,
the design is called covariate-adaptive. Finally, if we use all the past information, i.e.
allocations, covariates and responses of the patients and, also, the covariate of the present
patient before his allocation, we are in a covariate-adjusted response-adaptive (CARA)
design, see [78]. The σ-algebra containing the information used to assign the next patient
is denoted Fn. This information is different depending on the kind of design. Let
Gn = σ(δ1, . . . , δn) previous allocations,
Zn = σ(Z1, . . . , Zn) previous responses,
Hn = σ(H1, . . . ,Hn) previous covariates.
Then, if we are in a treatment-adaptive design, Fn = Gn, if the design is response-
3adaptive, Fn = σ(Gn,Zn). In case of covariate-adaptive designs, Fn = σ(Gn,Hn) and
finally, in CARA designs, Fn = σ(Gn,Zn,Hn+1).
The use of adaptive designs has an effect in the properties of the usual estimators,
due to the inclusion of dependence relations in the processes. Some partial results are
known. For instance, in [61] the consistency and asymptotic normality of the maximum
likelihood estimators for adaptive designs are ensured, under some conditions that emulate
those of the independence setting. A similar result is obtained in [43] for the least square
estimators. A more general result was developed in [51] and in [11]. They proved that
in the case of independent responses of the patients, if these responses are obtained in an
adaptive allocation process, they remain independent. Then, if the number of allocations
to each treatment tends to infinity, the estimators maintain the consistency and asymptotic
normality of the estimators in the independence setting.
Now, we make a presentation of several adaptive designs that will be used in the
contents of the thesis.
1.1.1 Complete Randomization
Complete randomization, (CR), is a non-adaptive randomization rule, where each treat-
ment has a probability of 1/2 to be assigned to a patient. When the patient arrives,
we throw a fair coin and the result of the coin determines the allocation. As we have
independent throws of a balanced coin, it is well known that
Nn,1
n
→ 1
2
, a.s.
and
2
√
n
(
Nn,1
n
− 1
2
)
→ N(0, 1) , [D],
where a.s. and D denote, respectively, almost sure convergence and convergence in distri-
bution.
One of the main drawbacks of complete randomization is a non-negligible probability
4of having an imbalance between treatment allocations, as stated in [63], Chapter 3. Those
imbalances affect the statistical precision of the analysis and decrease the power of the
statistical test. Due to this problem, some improvements were introduced in the allocation
rules, in order to mitigate the probability of large imbalance.
1.1.2 Treatment-adaptive randomization
Treatment-adaptive designs, sometimes also called in the literature adaptive designs, use
the previous treatment allocations to assign the next patient with the goal of increasing
the probability of balance. For instance, they give more probability to the treatment that
has been assigned fewer times. As a consequence, for all treatment-adaptive designs, we
have that
Nn,1
n
→ 1
2
, a.s.
Introduced in [19], Efron’s design was one of the first adaptive designs. When a patient
arrives, a biased coin is thrown. The probability of treatment 1 allocation changes de-
pending on the imbalance between the number of treatment assignments. It is p > 1/2 if
this treatment has been assigned fewer times in the past and 1 − p if the treatment has
been assigned more times. When both treatments have been equally assigned, a fair coin
is thrown. Denoting the imbalance of assignments as Dn = Nn,1 −Nn,2, then,
P (δn+1 = 1|Fn) =

p if Dn < 0 ,
1− p if Dn > 0 ,
1
2 if Dn = 0 .
(1.1)
The main goal of Efron’s design is to reduce the probability of imbalance between treat-
ment allocations. Efron suggested p = 2/3 as an optimal choice for the value of p. However,
the bias towards the under-represented treatment is the same regardless of the size of the
imbalance. In [70], Smith presented a design where the probability of assigning treatment
1 to the n-th patient is given by the next family of functions:
P (δn+1 = 1|Fn) = (Nn,2)
ρ
(Nn,1)ρ + (Nn,2)ρ
, ρ ≥ 0 . (1.2)
5As in Efron’s design, the probabilities are skewed to the under-represented treatment,
but in Smith’s design, the greater is the imbalance in the allocations, the bigger is the
probability of assigning the under-represented treatment. Thus, imbalance is corrected
faster. The value of the parameter ρ determines the degree of skewness of the allocation
function. Very large values could produce almost deterministic designs, Smith suggested
the value ρ = 5, which combines a fast convergence to balance and an acceptable level of
randomness.
A generalization of Smith’s designs, called ABCD designs, was proposed in [7]. They
use a family of functions F (Dn) : Z → [0, 1], decreasing and symmetric in the sense that
F (x) = 1− F (1− x), as an allocation rule.
Wei’s urn design was presented in [73] with the idea of obtaining a faster balance
between treatment allocations. The probabilistic tool used to randomize the allocation is
an urn. Initially, w balls of type 1 and w balls of type 2 are in the urn. Type 1 balls
are associated to treatment 1 and type 2 balls to treatment 2. When a ball is drawn, the
corresponding treatment is applied and the ball is returned to the urn along with α > 0
balls of the same type and β > 0 balls of the other type. Taking β > α the number of
balls of both types tends to be balanced. The replacement rule is summarized in a matrix,
called replacement matrix. The elements of the matrix are the number of added balls,
where rows indicate the extraction of the different type of balls and columns indicate the
effect in the different type of balls in the urn. The replacement matrix of Wei’s urn design
is
add add
type 1 type 2
balls balls
↓ ↓
Get type 1 ball →
Get type 2 ball →
 α β
β α
 .
6Then, the probability of assigning treatment 1 is
P (δn+1 = 1|Fn) = w + αNn,1 + βNn,22w + n (α+ β) . (1.3)
The Ehrenfest urn design was proposed for the first time in the context of clinical
trials in [12]. As in Wei’s urn design, initially the urn has w balls of each type, that is,
(W0,1,W0,2) = (w,w), where W0,i represents the initial number of type i balls in the urn.
When a new patient arrives, a ball is drawn from the urn, the patient is allocated to the
treatment associated with the type of ball and a ball of the other type is added to the urn.
Let Wn,1 and Wn,2 be the number of balls of type 1 and type 2, respectively, after the n-th
replacement. Observe that the total number of balls in the urn remains constant along
the process, Wn,1 +Wn,2 = 2w. The replacement matrix for the Ehrenfest urn design has
the following form,
type 1 type 2
↓ ↓
Get type 1 ball →
Get type 2 ball →
 −1 1
1 −1
 .
The probability of assigning treatment 1 is,
P (δn+1 = 1|Fn) = w −Nn,1 +Nn,22w . (1.4)
1.1.3 Response-adaptive randomization
As stated before, in response-adaptive randomization, each assignment is made using the
previous treatment allocations and the previous responses of the patients. The main pur-
pose of introducing the response information in the allocation rule is to improve the ethical
aspect of the experiment. As we are collecting the responses obtained from each treatment
application, we can promote the allocation to the treatment which is performing better
and, so, skew the assignments towards this treatment by increasing its allocation proba-
bility. This improvement in the ethics of the design makes more difficult the study and
7analysis of the design, because the dependence relationships among the different processes
of the design become more complex. There is a wide collection of response-adaptive de-
signs presented in the literature, good reviews can be found in [33] and [3]. Based on the
procedure to assign patients, two types of designs can be differentiated. On the one hand,
there are designs based on urn models. As some of the previous designs, such as Wei’s
urn design (1.3) and the Ehrenfest urn design, (1.4), the patient’s allocation is made by
drawing a ball from the urn, and the urn is updated taking into account the response of
the patient, see, for instance [45]. On the other hand, there are biased coin designs, in
which the probabilities of allocation of the different treatments are given by a function.
A target quantity for the proportion of treatment 1 allocations, ρ, is fixed beforehand,
and the probability of allocation varies in order to ensure the convergence to this target.
Usually, the target depends on some parameters related to the responses of the patients.
These quantities are commonly unknown, so they have to be estimated sequentially, and
due to this fact these designs are also called sequential estimation procedures.
The play-the-winner rule (PTW) was one of the first response-adaptive designs pre-
sented in the literature and also one of the most studied, see [75]. In this model, initially
we have an urn with ω balls of each treatment. When a patient arrives, a ball is extracted,
the corresponding treatment is applied and the response is observed. If the response is a
success, we return the ball along with β balls of the same treatment and α balls of the
other treatment, being β > α. In case of failure, we return the ball along with α balls
of the same treatment and β of the other one. With this replacement policy a success
is rewarded adding more balls of the applied treatment, and the failure is punished by
adding more balls of the other treatment. The replacement matrix is
 βZn,1 + α(1− Zn,1) αZn,1 + β(1− Zn,1)
αZn,2 + β(1− Zn,2) βZn,2 + α(1− Zn,2)
 . (1.5)
The probability of allocating treatment 1 can be expressed as
8P (δn+1 = 1|Fn) = w + α(Fn,1 + Sn,2) + β(Sn,1 + Fn,2)2w + n (α+ β) ,
where Sn,i and Fn,i are, respectively, the number of successes and failures in treatment i
up to and including the n-th patient. The limit allocation of treatment 1 is:
Nn,1
n
→ αp2 + βq2
α(p1 + p2) + β(q1 + q2)
, a.s.
Usually, α is taken as 0 and β is taken as 1, and then
Nn,1
n
→ q2
q1 + q2
=
1
q1
1
q1
+ 1q2
, a.s.
If p1 + p2 < 3/2 a central limit theorem is also obtained in [67],
√
n
(
Nn,1
n
− q2
q1 + q2
)
→ N(0, σ2), [D]
with
σ2 =
q1q2(5− 2(q1 + q2))
(2(q1 + q2)− 1)(q1 + q2)2 .
In [39] a modification of the play-the-winner rule is presented. It is called drop-the-loser
(DTL) rule. The allocation of patients is done with an urn. This urn contains three types
of balls, type 1 and type 2 corresponding to each treatment, and the so called immigration
balls, which are denoted as type 0 balls. When a ball is extracted, if it is an immigration
ball, we do not apply any treatment and the ball is returned along with one ball of each
of the other types. When a ball of type 1 or 2 is extracted, the corresponding treatment is
applied and the response observed. If it is a success, the ball is returned, with no change
in the urn composition. Otherwise, if it is a failure, the ball is not replaced. This model
punishes the failure by dropping balls, so the immigration balls are necessary to ensure
that the urn does not get empty. The replacement matrix is
Get type 0 ball →
Get type 1 ball →
Get type 2 ball →

0 1 1
0 Zn,1 − 1 0
0 0 Zn,2 − 1
 . (1.6)
9The limit of the proportion of treatment 1 allocations is the same as in the PTW rule,
with α = 0,
Nn,1
n
→ q2
q1 + q2
a.s.
A central limit theorem also holds for any p1 and p2,
√
n
(
Nn,1
n
− q2
q1 + q2
)
→ N(0, σ2), [D],
with
σ2 =
q1q2(p1 + p2)
(q1 + q2)3
.
This model was generalized in [77]. The main advantage of this generalization is that
after an immigration ball extraction, the number of type 1 and 2 balls added could be
different, allowing different asymptotic allocation ratios.
The randomly reinforced urn design (RRU), presented in [47] in a more general setting,
is based on an urn model which rewards a treatment when it is a success, tending to assign
the best treatment with probability 1. Initially, we have an urn with W0,1 balls of type 1
and W0,2 balls of type 2. When a patient arrives, a ball is extracted, the corresponding
treatment is applied and the response, Zn,i, is observed. Then we put back the ball along
with Zn,i balls of the same type. The replacement matrix stands as Zn,1 0
0 Zn,2
 . (1.7)
The proportion of treatment 1 assignments satisfies,
Nn,1
n
→ Z∞ a.s.,
being Z∞ = 1 if E(Zn,1) > E(Zn,2) and Z∞ = 0 if E(Zn,1) < E(Zn,2). The proportion
of assignments to the best treatment converges to 1. In case of equality between the
treatment responses, E(Zn,1) = E(Zn,2), Z∞ has a Beta distribution, β(W0,1, W0,2).
In [52] a very intuitive bias coin design is presented. The aim is to reach a fixed target
allocation, ρ, that depends on the unknown parameters of the design, usually p1 and p2.
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The target allocation is estimated in each step, and this estimation, ρˆn, is used as the
probability to assign patients. The allocation rule is
P (δn+1 = 1|Fn) = I {Un+1 < ρˆn} , (1.8)
being Un+1 a uniform distribution in [0, 1].
With this setting and under the assumptions that Nn,1 →∞ and Nn,2 →∞, the next
strong law is proven,
Nn,1
n
→ ρ .
A central limit theorem is also obtained,
√
n (pˆ1,n − pˆ2,n)→ N
(
0, (σ1 + σ2)
2
)
,
with σ1 =
√
p1(1− p1) and σ2 =
√
p2(1− p2). This design is called, in the sequel, Melfi-
Page-Geraldes or simply MPG.
In the MPG design, the allocation rule is clearly dependent on the estimation of the
target allocation. A more general family of biased coin designs are the doubly adaptive
designs. The idea of a doubly adaptive design (DBCD) was presented and studied in [20]
and [21]. The meaning of doubly adaptive is that in each step the proportion of allocations
is computed, the desired target allocation is estimated, and the probability of allocation
is given by a function depending on these two values. In [20], some conditions to this
probability function are given in order to ensure the convergence to the target allocation
ρ, and to obtain strong laws and central limit theorems for the treatment effect estimators.
Nevertheless, the conditions imposed on the allocation function were too stringent, and
in [35] an extension of the DBCD design is proposed, with the same idea, but relaxing
some of these conditions. The general performance is quite similar. In each step the
allocation proportion is computed and the target is estimated. By means of a function
g : [0, 1]× [0, 1]→ [0, 1] the probability of treatment 1 allocation is given. Imposing some
conditions on g, the next results are proven,
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Nn,1
n
→ ρ, a.s.
n1/2(Nn,1/n− ρ, ρˆn − ρ)→ N(0,Σ), [D],
where ρˆn is an estimator of the target allocation and Σ is the covariance matrix.
In [35], a family of functions, gα, is proposed, with the following general expression:
gα(x, y) =

1, x = 0,
0, x = 1,
y(y/x)α
y(y/x)α + (1− y)((1− y)/(1− x))α , (x, y) ∈ (0, 1)× [0, 1],
(1.9)
with α ≥ 0.
This function assigns in a deterministic way treatment 1 or 2 if the proportion of
allocations to treatment 1 is 0 or 1, respectively. In addition, if x > y, then, g(x, y) < y
guaranteeing the convergence to the target. The choice of the parameter α has also an
important role in the performance of the design. The case α = 0 corresponds to the
MPG design. The case α = ∞ has good asymptotic properties but it is completely
deterministic, so it is not recommended. The authors leave the choice of the value of α to
the practitioners, but in [62] α = 2 is advised.
The Efficient Randomized-Adaptive Design (ERADE), presented in [36], is a biased
coin design with the following allocation rule.
P (δn+1 = 1|Fn) =

αρˆn, if
Nn,1
n > ρˆn;
ρˆn, if
Nn,1
n = ρˆn;
1− α(1− ρˆn), if Nn,1n < ρˆn.
(1.10)
The conditional probability of treatment 1 allocation varies depending on the sign of
the difference between the current proportion of allocations and the estimation of the
target allocation. If the present proportion is equal to the estimation, the probability of
assigning treatment 1 is the estimation. If treatment 1 is overallocated, the probability is
the estimation penalized by a factor α which is in [0, 1) and if treatment 1 is underallocated,
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the probability is larger than the estimation, being also tuned by the parameter α. They
recommend selecting the value of the parameter α between 0.4 and 0.7.
The behavior of the allocation rule ensures the convergence of the proportion of treat-
ment 1 allocations, Nn,1n , to the target
Nn,1
n
→ ρ, a.s.
and a central limit theorem,
n1/2(Nn,1/n− ρ)→ N(0, σ2), [D].
One of the main differences between treatment-adaptive designs and response-adaptive
designs is the modification of the target allocation due to the inclusion of the responses
in the dynamics of the design. In the first family, all of them are oriented to reach the
equality of allocations between both treatments. In response-adaptive designs, the target
proportion of treatment allocations varies. In some designs, PTW or DTL for example,
the target allocation is given by the design itself, in this sense, they are ad-hoc procedures.
In other designs, ERADE or DBCD, for instance, the target allocation, ρ, is chosen by the
experimenter at the beginning of the trial, and the design targets this allocation. So, the
choice of ρ is fundamental in the properties of the design. In [64] a comparative study of the
performance and the optimality of different target allocations is done. A function f(p1, p2)
is chosen to compare the estimators of the parameters, pˆn,1 and pˆn,1, and a minimization
problem is raised: Find the allocation ratio that minimizes the expected number of failures
for a fixed asymptotic variance of f(pˆn,1, pˆn,2). Then, the optimal allocation is computed.
For instance, in the most usual case, when f(p1, p2) = p1 − p2, the optimal allocation
is
√
p1√
p1+
√
p2
, (RSIHR allocation in the sequel). In this paper other limit allocations are
also mentioned. On the one hand, Neyman allocation,
√
p1q1√
p1q1+
√
p2q2
, which minimizes the
variance of the sample proportions. This allocation also minimizes the sample size when
a power level is fixed. On the other hand, the urn allocation, q2q1+q2 , which is not optimal
with any criterion, but can be interpreted as the relative risk of failure. The most usual
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allocation used to compare designs is the RSIHR allocation. It is optimal from the ethical
point of view and maintains low levels of variance of the estimators. Neyman allocation
is optimal with an inferential criterion but if p1 + p2 > 1, allocates more patients to the
inferior treatment, which is unethical, and the urn allocation, although is not optimal in
any sense, is often used for comparisons involving urn designs.
Balance between ethical purposes and good inferential properties is desirable. These
two goals are competitive, because in order to improve the ethical aspect of the design,
more patients are assigned to the best treatment and then, balance is not possible except
for equal performance. This fact decreases the amount of information of the other treat-
ment, usually increasing the variance of the treatment effect estimators which produces
lower power levels in the test statistics.
As stated in [33], one of the main issues in response-adaptive randomization is the
ability to minimize the expected number of failures without a loss in the power. In line with
this, in [32], they derived an explicit relationship between the variance of the proportion
of treatment 1 allocations and the power function of the classical test of difference of
means. Using a series expansion of the noncentrality parameter, they obtain that the power
function is linearly related to V ar(Nn,1/n), and if the variance increases, the noncentrality
parameter decreases, with a loss in the power of the test. This result is strongly linked to
the limit allocation, so the variance of Nn,1/n could be used as a measure of goodness of
the design from the inferential point of view, but only when comparing designs with the
same limit allocation.
In [34] a lower bound on the asymptotic variance of the allocation proportion is derived.
Using a Cramer-Rao type bound and under asymptotic normality of the allocation propor-
tion, they give a minimum value for the variance. This bound depends on the asymptotic
proportion of allocations and it becomes a good tool to compare different designs with
the same target allocation. If the proportion of treatment 1 allocations converges almost
surely to a value ρ(p1, p2) and a central limit theorem can be applied, then the lower bound
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for the variance of Nn,1/
√
n is(
δρ(p1, p2)
δp1)
)2 p1q1
ρ(p1, p2)
+
(
δρ(p1, p2)
δp2)
)2 p2q2
(1− ρ(p1, p2)) .
For urn allocation, q2q1+q2 , the lower bound of the variance is
q1q2(p1 + p2)
(q1 + q2)3
.
For Neyman allocation the bound is
1
4
(√
p1q1 +
√
p2q2
)3 (p2q2(q1 − p1)2√p1q1 + p1q1(q2 − p2)
2
√
p2q2
)
and for RSIHR allocation,
1
4
(√
p1 +
√
p2
)3 (p2q1√p1 + p1q2√p2
)
.
In DBCD design with α = 2, the lower bound is not reached for any of the previous
allocations. If α → ∞ the bound is achieved but the design is almost deterministic.
However, in ERADE designs, the lower bound is reached for any chosen target allocation.
Asymptotic efficiency is the most remarkable property of these designs. In the DTL design,
the lower bound for the urn allocation is also reached asymptotically.
The idea of comparing different designs to establish which is the best one is a complex
task in response-adaptive randomization, due to the competitiveness between ethical and
inferential properties. The usual approximation is looking for a good compromise between
both criteria. Either fix one criterion and optimize the other one or a joint optimization of
a convex combination of them are the common strategies. In [15], the equivalence between
these two approaches is proven.
A deep comparative computational study among response-adaptive designs was done
in [62]. The complete randomization design is used as a benchmark to establish the
sample size required to have a 90% of power in the classical test for the difference of
success probabilities. The comparison is made by using the following two criteria: the
total number of failures, as an ethical criterion, and the power of the test, as an inferential
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criterion. Firstly, the DTL rule and the PTW rule are compared. As both of them have
the same target allocation, the expected number of failures is similar but the DTL rule
shows a higher power. So, the superiority of this rule is confirmed. Another comparison
is done involving the DBCD design, with three values of the parameter, α = 0, α = 2
and α = ∞. In this comparison the value α = 2 seems to be the most advisable, due to
the fact that it has very good levels of power and expected failures, with enough level of
randomness. Finally, comparing the DTL rule and the DBCD with α = 2, the values of
both criteria are quite similar, being impossible to determine clearly which is the best one.
In [24] a comparison study is made by using graphical tools. Here, the main idea is to
compute two measures, one about ethics and the other one about estimation, drawing the
results in a two axis plot. These measures are the expected proportion of allocations in the
worst treatment and the root mean-square-error of the estimation of the treatment effects
difference. The optimality consists in minimizing at once both measures, so, a global
measure of optimality is the distance to the origin. The comparison is made for the most
significant response-adaptive designs and they conclude that ERADE designs and DBCD
designs have the best performance. They also mention that, among the designs that do
not target any optimal allocation, the DTL rule performs the best and is competitive with
ERADE and DBCD.
1.2 Randomization based inference
The main objective of a phase III clinical trial is to evaluate the superiority of the treatment
under study against the control treatment. In order to make the decision, a statistical test
can be used. A frequently used statistical test in this kind of experiments is the classical
Wald test for the difference of means,
pˆn,1 − pˆn,12 − (pn,1 − pn,2)√
pˆn,1(1− pˆn,1)
Nn,1
+
pˆn,2(1− pˆn,2)
Nn,2
.
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Although the distribution of this statistic is unknown in the adaptive case, assuming a
population model a normal approximation can be used, in the conditions of [11]. In
a population model, patients are assumed to come from two different populations and
they are chosen from these populations by a random sampling procedure. However, a
peculiarity of clinical trials is the sampling procedure, that differs from the usual one in
the majority of statistical experiments. The population of reference is the people who
meet suitable requirements in order to participate in the trial. In addition, they must be
localized in the area of the centers where the trial is carried on. After that, during the
different phases of the study, patients could decline participating in the trial or clinicians
could have a negative opinion about a patient and they can rule him out. So, in fact, the
sample is formed by all the patients who meet eligibility criteria, are localized, give their
consent and are accepted by the clinicians. After that, these patients are allocated in the
treatments by the randomized allocation rule of the design and the study is carried out.
Note that the only randomness of the whole process is due to the random allocation rule
and the sampling process is quite deterministic. This is the reason why the acceptance of
a population model, with two different populations and random sampling of patients, is
controversial.
An alternative to the population model is the randomization model, which uses the
randomization as a basis for inference. A good explanation about randomization based
inference (RBI) is given in [18]. Given the experimental data, x, for which no parametric
assumption is done, a statistic T (x) is computed. Then, the data are permuted repeatedly
in a manner consistent with the random assignment procedure, and the statistic is com-
puted for each of the resulting data permutations. Suppose that a one-sided significance
test with significance level α is applied to accept or reject a null hypothesis. The null
hypothesis for a randomization test is that there is no difference in the observed outcomes
whatever the allocation, which can be seen as a nonparametric counterpart of the para-
metric hypothesis of equality of success probabilities. RBI proceeds by computing the
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probability that the random assignment procedure provides a reallocation for which the
test statistic is greater than the observed value T (x). In other words, the p-value associ-
ated with T (x) is computed. If this probability is smaller than α, the null hypothesis is
rejected.
The origin of randomization in the design of experiments and the concept of ran-
domization test can be found in Fisher’s work in the 1930’s. Since then, it has been a
controversial statistical issue. In [8] a good review about the origin, development and
criticisms of randomization is done. Focusing more on permutation tests, in [56], along
with a solid theoretical basis for permutations tests, some classical criticisms about this
inferential procedure are presented, but their adequacy in some cases is vindicated.
In the context of clinical trials, following [63], the null hypothesis of a randomization
test is no difference between both treatments. So, the assignment of the treatments does
not affect the responses of the patients, and they are assumed fixed. Then, the only
randomness left comes from the patients’ allocations.
Another important statistical issue when randomization tests are used concerns the use
of conditional or unconditional tests. Conditional tests assume that the decision must be
made with the p-value of the test statistic conditioned to the number of patients allocated
in treatment 1, that is, the distribution of T (x)|{Nn,1 = n1} must be calculated instead
of the unconditional distribution of T (x). The use of conditional tests is advised by Cox
in [16] when the number of patients allocated to each treatment is ancillary, as it happens
for treatment-adaptive designs. However, with response-adaptive designs, the distribution
of Nn,1 depends on the success probabilities and, so, it is not ancillary and the use of
conditional tests is not justified with Cox’s arguments. But in [9], where results in [74]
are analyzed, the use of conditional tests is considered more appropriate also for response-
adaptive designs, but always under heuristic arguments.
RBI requires the computation of the test statistic for all the possible allocations of
patients and, also, the calculation of the probability for each possible arrangement of al-
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locations, when arrangements are not equally probable. This could be computationally
unfeasible, and becomes the main drawback of RBI. In order to avoid this problem, sev-
eral techniques have been presented. In [49] and [57], Monte Carlo methods are used to
compute p-values via approximation. Another usual technique consists in programming
algorithms to shorten the calculations of all the permutations, using recurrence relations.
In [31] an algorithm to compute the exact distribution of the randomization test statistic
for the Smith class of designs is given and in [50] another algorithm is presented based
on networks in order to obtain the exact distribution for Wei’s urn design. It should be
mentioned that these recursive algorithms are very tied to the particular class of designs
analyzed, because the recursive rules are based on relations originated from the allocation
probabilities. For response-adaptive designs these relations could be more complicated,
due to the inclusion of responses in the allocation rule. Less work has been done in this
field. In [74] the exact distribution of the test is computed for the play-the-winner rule
and in [23] for the drop-the-loser rule. In some cases, with very large sample sizes, this
recurrence relations are computationally unfeasible, so, an alternative is to obtain the
asymptotic distribution of the test statistic. As the responses are a deterministic set, en-
suring an asymptotic distribution for all the possible score sets is almost impossible and
some conditions on them are required. In addition, all the procedures for obtaining the
asymptotic distributions of these statistics depend strongly on the randomization rule.
For instance, in [71] a central limit theorem is obtained for the randomization statistic
when Wei’s urn design is applied. They also prove with a counterexample that for some
set of scores the statistic is not normal if Efron’s design has been applied.
1.3 Covariates in clinical trials
In the design and analysis of a clinical trial, there is additional patient information that
should be taken into account. The covariates or prognostic factors give us more information
about patients, and can influence the patients’ response to the treatment. Gender, age,
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clinical centre or some health indicators related to the disease could be associated to the
response that we are studying. An imbalance between covariate levels could produce a bias
in the study. Randomization itself protects against these imbalances, because the random
rule asymptotically distributes equally patients between treatments. For instance, in [63]
a measure of covariate imbalance is presented,
∆Fn :=
n∑
i=1
δiHi
Nn,1
−
n∑
i=1
(1− δi)Hi
Nn,2
, (1.11)
and they give conditions to prove P (|∆Fn| > ε)→ 0. But this is an asymptotic property
and in moderate sample sizes large imbalances could appear, biasing the study. Several
solutions have been presented in order to avoid or mitigate this bias, as including the
covariates in the design, or analyzing the results taking into account these covariates.
Good reviews of the use of covariates in adaptive designs can be found in Chapter 4 of
[63] and in [65].
Stratification is a common approach to include the covariate information. In a strat-
ified design, the strata are defined using the different covariate levels. These strata are
considered separately, each one with its proper randomization rule. When a patient arrives
to the study, he is assigned to a stratum according to his covariate information and the
rule of this stratum is used to assign him to a treatment. Stratification also could be done
in a post-randomization stage, comparing the different treatments within each strata and
then combining the whole information in a unique procedure.
Another different approach is the so-called covariate-adaptive randomization. In this
setting, the covariate information is included in the general randomization rule, to min-
imize the imbalance between the different groups. Formally, the (n + 1)-th patient is
allocated depending on the previous allocations and covariates and his/her covariates, so
Fn = σ(Gn, Hn+1).
The use of covariates in randomization rules was first proposed in [59]. The perfor-
mance of the rule is very similar to the Efron’s biased coin desing, but measuring covariate
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imbalances instead of treatment imbalances. The main idea is to define an imbalance met-
ric, Dn, which measures the total imbalance between groups, with a weighted sum of the
imbalance in each group. Then, the allocation rule is
P (δn+1 = 1|Fn) =

p if Dn < 0 ,
1− p if Dn > 0 ,
1
2 if Dn = 0 .
In [37] a version of the Pocock and Simon’s model is presented an its properties are
studied. The lack of theoretical work in covariate-adaptive randomization has been re-
marked in several papers, for instance, in [37] and in [65].
The model-based approach for handling covariates was proposed in [10] and in [2]. In
these papers, a linear model is assumed for the responses of the patients. This model
considers the linear influence of the allocations and the covariates of interest. Then, if n
patients have been allocated, the (n+1)-th patient is allocated to minimize the variance of
the treatment effect. In [10], this version of the design was presented, being a deterministic
rule, and in [2] a randomized version was studied. In [70] the theoretical basis for these
designs was developed.
When the (n + 1)-th patient is allocated depending on the previous responses, al-
locations, covariates and, also, her/his own covariates, the information is collected as
Fn = σ(Zn, Gn, Hn+1). Then, we say that the rule is covariate adjusted response-adaptive
(CARA). A seminal paper which relates covariates and adaptive designs is [66], where a
treatment effect is used to allocate the next patient to a treatment. More precisely, they
consider two treatments with dichotomous responses, and they assume a logistic response
model with parameters α, β, γ = (γ1, . . . , γM )t, θ = (θ1, . . . , θM )t:
logit(P (Yn = 1)) = α+ βδn +Htnγ + δnH
t
nθ ,
where Hn is the vector which contains the patient’s covariate information. Given the
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maximum-likelihood estimators of the parameters, they allocate the next patient using
P (δn+1 = 1|Fn) = 1
1 + e−(βˆn+H
t
n+1θˆn)
which is a function of the estimated covariate-adjusted odds ratio between treatments.
They show, using a simulation study, that this rule skews allocation to the best treatment
and has less failures than equal allocation.
Several asymptotic properties of a class of covariate adjusted response-adaptive designs
have been studied in [78]. These designs assume a parametric model and have a target
allocation, which is a function of some parameters of the model. The patient’s response
to treatment j, Ynj , satisfies
E[Yn,j |Hn] = p(θj , Hn) .
where θj are the parameters of the model. Then, the allocation rule is a function of the
covariates, which are known, and of the parameters, which can be estimated using the
accrued information.
P (δn+1 = 1|Fn) = pi(θˆ, Hn)
Asymptotic results for estimators and for the proportion of successes (by stratum, by
treatment) are obtained for this class of designs, which includes the setting in [66].
Chapter 2
Klein urn design
A randomized controlled clinical trial is a statistical experiment to compare the efficacy of a
new treatment, say treatment 1, with respect to a control treatment, say treatment 2. The
control treatment is the best clinical practice known or a placebo. Patients are assumed
to arrive sequentially to the experiment and, following a random rule, are allocated in
treatment 1 or treatment 2. When the allocation rule uses previous information to allocate
the following patient, the design is called adaptive. Adaptive designs could be classified
according to the previous information which is used. Following [63], we say that a design
is treatment-adaptive if it uses information about past allocations, and we say that it is
response-adaptive if it also uses information of the past responses of patients to treatments.
The Ehrenfest urn design, see (1.4), is a treatment-adaptive design that uses the previous
allocations in order to assign treatment 1 or 2 to the next patient. Its limit allocation
for each treatment is 1/2. If the result of a treatment can be observed before the arrival
of the next patient, the information accrued from the previous individuals can be used
to improve the performance of the experiment. Some modifications of the Ehrenfest urn
design which use this information are presented in this chapter. In the first scenario, S1,
a treatment is reinforced when is successful. This rule mimics the Randomly Reinforced
Urn model, RRU, see (1.7). In the second scenario, S2, a treatment is reinforced if it is a
success or if the other treatment is a failure. This is the randomized Play-The-Winner rule,
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PTW, which has been profusely studied, see (1.5). In scenario S3 a treatment is reinforced
if the other treatment is applied and it is a failure. This rule is similar to the Drop-The-
Loser rule, DTL, see (1.6). Exact and asymptotic properties of these three scenarios are
obtained, and their performance is compared with their inspiring rules. Scenario S3 has
a similar behavior to the DTL rule in the number of failures and power and also in the
variability of allocations. Besides, it has the same target allocation as the DTL rule, which
is widely accepted as a competitive response-adaptive design, see [34] and [24]. Therefore,
scenario S3 deserves a thorough study, which is done in the last section of this chapter.
The urn composition of S3 is a homogeneous Markov chain which was studied by Klein
in [41] out of the context of clinical trials, as a generalization of the Ehrenfest urn model.
This scenario S3 will be called Klein urn design in what follows.
The contents of this chapter have been published in [27] and [26].
2.1 Response-adaptive designs based on Ehrenfest urn
The Ehrenfest urn design, see, for instance, (1.4) or [12] for the original paper, is a
treatment-adaptive design that uses the previous information in the following way. Initially
the urn contains w balls of each type, that is, (W0,1,W0,2) = (w,w). When a new patient
arrives, a ball is drawn from the urn, the patient is allocated to the treatment associated
with its type and a ball of the other type is added to the urn. Observe that the total num-
ber of balls remains fixed after each replacement. So that, for each n, Wn,1 +Wn,2 = 2w
and Wn,1 describes completely the composition of the urn. The composition of the urn
depends only on the number of times that each treatment has been applied.
Mean and variance can be calculated, at any stage n of the procedure, for the processes
{Wn,1} and {Nn,1} associated with the Ehrenfest urn design, see [5], and are
E[Wn,1] = w, V ar[Wn,1] =
w
2
(
1−
(
1− 2
w
)n)
,
and also,
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E
[
Nn,1
n
]
=
1
2
, V ar
[
Nn,1
n
]
=
w
8n2
(
1−
(
1− 2
w
)n)
.
Observe that the process {Wn,1} is a time homogeneous Markov Chain with state space
E = {0, 1, . . . , 2w} and transition matrix P = (pi,j), where
pi,j =
 1−
i
2w , j = i+ 1;
i
2w , j = i− 1;
i = 0, 1, . . . , 2w. (2.1)
This property can be exploited, see [6], to obtain strong laws and central limit theorems.
In particular, the following central limit theorem holds,
√
n
(
Nn,1
n
− 1
2
)
→ N
(
0,
σ2
(2w)2
)
, [D]
where σ2 can be expressed in terms of the eigenvalues and eigenvectors of the transition
matrix of the Markov Chain {Wn,1}.
Three modifications of the Ehrenfest urn design are introduced in this section, in which
depending on the response of the patient, the extracted ball is replaced or not. In the three
scenarios we consider an urn that, initially, contains W0,1 balls of type 1, and 2w −W0,1
balls of type 2. W0,1 could be any random variable with values in E = {0, 1, . . . , 2w},
but usually we assume that W0,1 = w. The total number of balls remains constant,
Wn,1 +Wn,2 = 2w, for any n, so as in the Ehrenfest urn model, Wn,1 describes completely
the state of the urn. {Wn,1} is a discrete time stochastic process which takes values in the
set E = {0, 1, . . . , 2w}. As the urn replacement policy only depends on the past history of
the process via the last state, {Wn,1} is clearly a Markov chain. We present a description
of each scenario along with the transition probabilities of the Markov chain {Wn,1}.
2.1.1 Scenario 1 (S1 design)
In scenario S1 a treatment is reinforced when it is successful. As stated in the introduction,
the RRU designs, (1.7), uses an unbounded urn, and the proportion of patients allocated in
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the best treatment converges to 1 almost surely. When both treatments perform equally,
it converges to a beta distribution β(w, w).
The reinforcement policy has to be adapted to obtain an urn with a constant number
of balls, 2w. When the urn is in an interior state, that is, when Wn,1 ∈ E \ {0, 2w}, if
the treatment applied is a success, we add a ball of its type and we remove a ball of the
other type. If the treatment is a failure, the composition of the urn remains unchanged.
The transition matrix of {Wn,1} derived from the S1 rule is P = (Pi,j) i, j ∈ E, where
pi,j =

p1
i
2w , j = i+ 1;
q1
i
2w + q2(1− i2w ), j = i;
p2(1− i2w ), j = i− 1;
0, otherwise,
i = 1, . . . , 2w − 1 . (2.2)
When Wn,1 = 0 or Wn,1 = 2w, additional rules are needed. If the treatment applied is
a success, the urn remains unchanged. If it is a failure, we remove a ball of its type and
we add a ball of the other type. So, the states 0 and 2w are considered as semi-reflecting
barriers, that is
p0,0 = p2, p0,1 = q2
p2w,2w = p1, p2w,2w−1 = q1.
(2.3)
2.1.2 Scenario 2 (S2 design)
In scenario S2 a treatment is reinforced if it is a success or if the other treatment is
a failure. This rule corresponds with the randomized PTW rule, (1.5), presented in the
introduction. In the PTW rule an unbounded number of balls in the urn is also considered
and the proportion of patients allocated in treatment 1 converges to q2/(q1 + q2); that is,
the ratio of allocations to a treatment converges to its relative risk of failure.
The reinforcement policy has to be adapted to obtain an urn with a fixed number of
balls, 2w. When the urn is in an interior state, Wn,1 ∈ E \ {0, 2w}, we add a ball of type
1 and remove a ball of type 2 if treatment 1 is applied and it is a success or if treatment
2 is applied and it is a failure; treatment 2 is reinforced in a similar way: if treatment 2 is
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applied and it is a success or if treatment 1 is applied and it is a failure. In this case, the
transition matrix P of the MC {Wn,1} is
pi,j =

p1
i
2w + q2(1− i2w ), j = i+ 1;
p2(1− i2w ) + q1 i2w , j = i− 1;
0, otherwise,
i = 1, . . . , 2w − 1 . (2.4)
When Wn,1 = 0 or Wn,1 = 2w, we proceed as in (2.3):
p0,0 = p2, p0,1 = q2
p2w,2w = p1, p2w,2w−1 = q1.
2.1.3 Scenario 3 (S3 design)
In scenario S3 a treatment is reinforced if the other treatment is applied and it is a failure.
This rule is similar to the DTL rule, (1.6). The DTL rule has the same allocation limit
as the PTW rule; that is, the proportion of patients allocated to a treatment converges to
its relative risk of failure.
The transition matrix P under the S3 design is
pi,j =

q2(1− i2w ), j = i+ 1;
p1
i
2w + p2(1− i2w ), j = i;
q1
i
2w , j = i− 1;
0, otherwise,
i = 0, . . . , 2w. (2.5)
The urn remains unchanged if the treatment applied is a success. If it is a failure, we
remove a ball of this type and we add a ball of the other type. Note that, in this scenario,
the barrier conditions of the previous scenarios implicitly hold, due to the fact that the
general rule could be applied in the border states. Transition matrix (2.5) was already
considered in [41].
Remark 2.1.1. The semi-reflecting barrier conditions established in S1, S2 and S3 designs
seem quite logical in the spirit of a clinical trial. If Wn,1 = 0 the urn contains 2w balls of
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type 2, and treatment 2 is applied until a failure happens. If Wn,1 = 2w the urn contains
2w balls of type 1, and treatment 1 is applied until a failure happens. On the other
hand, absorbent barriers, the case that the Markov chain gets stuck when it hits a barrier,
would force to apply the same treatment once the barrier is reached until the end of the
trial, which is a deterministic rule for a clinical trial. This introduces biases in the study,
so it is not a viable alternative. Completely reflecting barriers, the case that the chain
automatically moves to the adjacent state when it hits a barrier, makes the urn process
to be deterministic when the barrier is reached. In these cases, regardless the response
of the patient, the urn would move like if a failure had happened, losing the connection
between the urn and the performance of the treatments.
As stated in [32], “Any new procedures proposed should fully investigate operat-
ing characteristics, including the target allocation, expected failure rate, variability, and
power”. Also in [32], the study of asymptotic properties is enhanced. After presenting the
three designs, checking their properties should be an mandatory step, comparing them
with another designs in the literature. Comparative studies rely heavily on asymptoti-
cal properties or on simulation studies. Checking asymptotic properties of the designs is
essential, as mentioned in [32], “is important to check the accuracy of the asymptotic ap-
proximations when using these theoretical results to compare designs”. So, it is of interest
and necessary to carry out a study of the asymptotic properties of S1, S2 and S3 designs.
On the other hand, it is also important to know some exact information about the
operating characteristics in any step n of the process. Some clinical trials could have
small sample size, which prevents the use of asymptotic results. Besides this, even in
trials involving large quantities of patients, information about the behavior in early steps
is useful. But, in general, exact values, for example the mean and the variance of the
number of allocations for each n, are difficult to obtain when adaptive designs are applied,
due to the complicated correlation structure generated between allocations and observed
responses. However, in S1, S2 and S3 designs, some exacts results are obtained.
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The next proposition deals with the asymptotic behavior of the {Wn,1} process, which
is based on some classical results of Markov chains.
Proposition 2.1.1. Under the three scenarios, the process {Wn,1} has the following prop-
erties.
a) It is an aperiodic and irreducible Markov chain and there exists a stationary distri-
bution pi = {pii}i∈E
b) A strong law holds
1
n
n−1∑
k=0
Wk,1 → pi∗, a.s.
where pi∗ :=
∑
i∈E
ipii is the mean value of the stationary distribution. Besides, for m > 1,
1
n
n∑
k=1
Wmk,1 → pi∗m, a.s.
where pi∗m :=
∑
i∈E
impii.
c) A central limit theorem holds
1√
n
(
n−1∑
k=0
Wk,1 − npi∗
)
→ N(0, σ2).
where σ2 = limn→∞ 1nV ar
[
n∑
k=1
Wk,1
]
.
Proof. The chain is clearly irreducible and aperiodic under the three scenarios. Since
the state space is finite, the chain is positive recurrent. The existence of the stationary
distribution is given by the Lemma III.2.1 in [38] and will be denoted pi = {pii}i∈E . For
the strong law, note that
1
n
n∑
k=1
Xk =
1
n
∑
i∈E
i n(Xk = i)
where n(Xk = i) is the number of visits to the state i. Following proposition 2.21 in [14],
the result is immediate. Finally, the c) part is a particular case of the so called CLT for
Markov chains; see, for instante Theorem 10.2 in [17].
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In the following proposition we give an explicit expression of the distribution probabilities.
Proposition 2.1.2. For the Markov chain {Wn,1}, the stationary distribution pi satisfies:
a) for scenario 1, (S1),
pii
pi0
=
q2
p2
(
p1
p2
)i−1 2w(
2w−1
i−1
)
(2w − i) , i = 1, . . . , 2w − 1
pi2w
pi0
=
q2
q1
(
p1
p2
)2w−1
.
b) For scenario 2, (S2),
pii
pi0
=
i−1∏
j=0
q2 + (p1 − q2) j2w
2w−1∏
j=2w−i
q1 + (p1 − q2) j2w
, i = 1, . . . , 2w .
c) For scenario 3, (S3), pi is the probability mass distribution of a binomial distribution
with parameters 2w and q2/(q1 + q2).
Proof. As the transition matrix for the S1, S2 and S3 is tridiagonal, following the example
(b) of page 396 in [22], we obtain,
pii
pi0
=
i−1∏
j=0
pj,j+1
pj+1,j
, i = 1, . . . , 2w, pi0 =
1
1 +
2w∑
i=1
pii
pi0
.
If we substitute in this expression (2.2), (2.4) and (2.5), the transition probabilities of each
scenario, we prove the three results. In S1, for each state i < 2w, we can use pj,j+1 = p1 j2w
and pj+1,j = p2
(
1− j+12w
)
so plugging these expressions in the general equation, and
noting that p0,1 = q2 due to the barrier conditions, we have that
i−1∏
j=0
pj,j+1
pj+1,j
=
q2
i−1∏
j=1
p1
j
2w
i−1∏
j=0
p2
(
1− j + 1
2w
) = q2p2
(
p1
p2
)i−1 (i− 1)!
i−1∏
j=0
(2w − (j − 1))
=
q2
p2
(
p1
p2
)i−1 2w(
2w−1
i−1
)
(2w − i) .
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The closed expression for i = 2w, S2 and S3 are obtained with the same procedure.
Remark 2.1.2. Observing the expressions in the previous proposition, we note that when
p1 = p2 = p, the stationary distribution is symmetric for the three scenarios. So that,
pi∗ = w. Besides this, if the starting distribution is symmetric, then the probability
distributions of {Wn,1} are symmetric for any n ≥ 0, due to the symmetry of the transition
matrix for each scenario. For scenario S2, when p = 0.5 we have that pi follows the uniform
distribution on the set {0, 1, . . . , 2w}.
The expressions for the stationary distribution in the last proposition allows us to im-
plement them and obtain a visual approach about how the probability mass is distributed.
In Figures 2.1 and 2.2, the stationary distribution for S1 and S2 is shown for selected values
of p1 and p2.
Figure 2.1: Stationary distributions of {Wn,1} in S1
In S1 the different stationary distributions can be divided into two different groups,
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Figure 2.2: Stationary distributions in S2
being Figure 2.1 a sample of them. In the case of different success probabilities, the
probability mass is completely accumulated in larger states of E, that is, a larger amount
of balls of the best treatment is more probable in the stationary case. If the difference
between both probabilities is small, then a small amount of probability appears in the
border state of the worst treatment, as we can see in the 0.8-0.7 case shown in Figure
2.1. When both are equal, the distribution is symmetric, as we know from the explicit
expressions, and completely accumulated in the smaller and larger states of the chain.
For the case S2, we can observe more variety of distributions. Under equal success
probabilities, if p1 = p2 > 0.5 then the distribution has a U form like in the previous sce-
nario. If p1 = p2 < 0.5 the distribution has a bell shape, concentrating more probability in
the central states, due to the low success probabilities. The limit case p1 = p2 = 0.5 is the
uniform distribution, as stated in Remark 2.1.2. In the case of different success probabil-
ities, the distribution is skewed towards the best treatment, being this more pronounced
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with larger success probabilities.
A closed expression for the mean and variance of the stationary distribution for each
scenario is of interest. In the following proposition, by means of a recurrence relationship,
explicit expressions of pi∗, the mean of the stationary distribution is presented for each
scenario.
Proposition 2.1.3. We consider the Markov chain {Wn,1} and assume that W0,1 = w.
Then,
a) for scenario 1, S1,
pi∗ =
2w
p1 + p2
(p2 + pi2w − pi0)
b) for scenario 2, S2,
pi∗ =
w
q1 − p2 (q2 − p2 + p2pi0 − p1pi2w)
c) for scenario 3, S3,
pi∗ = 2w
q2
q1 + q2
Proof. Once the response of the kth patient is obtained, we denote as I+k the indicator
variable of adding one ball of type 1 to the urn and I−k the indicator variable of removing
one ball of type 1 from the urn. We can write the following recurrence equation
Wn+1,1 = Wn,1 + I+n+1 − I−n+1. (2.6)
Note that
E[I+n+1|Wn,1] =
2w−1∑
i=1
pi,i+1I{Wn,1=i} + q2I{Wn,1=0},
E[I−n+1|Wn,1] =
2w−1∑
i=1
pi,i−1I{Wn,1=i} + q1I{Wn,1=2w}.
Expectations are taken in (2.6) and we have that
E[Wn+1,1] = E[Wn,1] +
2w−1∑
i=1
(pi,i+1 − pi,i−1)pnw,i + q2pnw,0 − q1pnw,2w. (2.7)
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On the other hand, for i = 1, . . . , 2w − 1, and depending on the scenario,
pi,i+1 − pi,i−1 =

−p2 + p1 + p22w i, for S1 ,
−(p2 − q2) + p1 − q2
w
i, for S2,
q2 − q1 + q22w i, for S3 .
(2.8)
So that, pi,i+1 − pi,i−1 = a1 + b1i, where a1 and b1 are constants determined in (2.8)
depending on the scenario. Then, (2.7) becomes:
E[Wn+1,1] = (1 + b1)E[Wn,1] + a1 + (q2 − a1)pnw,0 − (q1 + a1 + 2wb1)pnw,2w, (2.9)
which is the recurrence relation for E[Wn,1] that we were looking for.
Taking limits in (2.9) we have
pi∗ =
a1 + (q2 − a1)pi0 − (q1 + a1 + 2wb1)pi2w
−b1 (2.10)
and a), b) and c) follow plugging in (2.10) the coefficients given in (2.8).
Remark 2.1.3. Using the same procedure we can get also a recurrence expression for
E[W 2n+1,1]. From (2.6) we have
W 2n+1,1 = W
2
n,1 + I
+
n+1 + I
−
n+1 + 2Wn,1(I
+
n+1 − I−n+1), (2.11)
Taking expectations in (2.11) we obtain
Ew[W 2n+1,1] = Ew[W
2
n,1] +
2w−1∑
i=1
(pi,i+1 + pi,i−1)pnw,i + q2p
n
w,0 + q1(1− 4w)pnw,2w
+2
2w−1∑
i=1
i(pi,i+1 − pi,i−1)pnw,i . (2.12)
Note that, for i = 1, . . . , 2w − 1, and depending on the scenario,
pi,i+1 + pi,i−1 =

p2 +
p1 − p2
2w
i, for S1,
1, for S2,
q2 +
q1 − q2
2w
i, for S3.
(2.13)
34
So that, pi,i+1 + pi,i−1 = a2 + b2i, where a2 and b2 are constants determined in (2.13) for
each scenario. Now we can rewrite (2.12) as follows,
E[W 2n+1,1] = (1 + 2b1)E[W
2
n,1] + a2 + (b2 + 2a1)E[Wn,1]
+(q2 − a2)pnw,0
+(q1 − a2 − 2b2w − 4a1w − 8b1w2 − 4wq1)pnw,2w (2.14)
which is the recurrence relation for E[W 2n,1].
Remark 2.1.4. A closed expression for the solution of (2.9) is easy to obtain for the S3
design:
E[Wn,1] = pi∗ + rn(w − pi∗),
where r = (1− q1 + q2
2w
). As Nn,1 =
n∑
k=1
δk, we have
E[Nn,1] = E
[
n∑
k=1
δk
]
=
n∑
k=1
E[E[δk|Fk−1] = 12w
n−1∑
k=0
E[Wk,1] (2.15)
and then, plugging the previous expression for E[Wk,1] in 2.15, we obtain
E[Nn,1] = n
pi∗
2w
+
1− rn
1− r
(
1
2
− pi
∗
2w
)
.
Proposition 2.1.4. We have the next strong laws,
a) for scenario 1, S1
Nn,1
n
→ (p2 + pi2w − pi0)
p1 + p2
a.s.
b) for scenario 2, S2
Nn,1
n
→ (q2 − p2 + p2pi0 − p1pi2w)
2(q1 − p2) a.s.
c) for scenario 3, S3
Nn,1
n
→ q2
q1 + q2
a.s.
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Proof. From Proposition 2.1.1, we have the almost sure convergence of the {Wn,1} process.
Applying Theorem 1 in [6], we have the following result for the three scenarios.
Nn,1
n
→ pi
∗
2w
, a.s.
Using Proposition 2.1.3, we have the explicit values of pi∗, and we get the result.
Remark 2.1.5. Observing the limiting values of the proportion of values, some facts could
be observed. On the one hand, in S1 and S2 designs, this limit depends strongly on the
stationary probabilities of the border states of the urn, and this dependency disappears
in the third scenario. On the other hand, the limit in S3 is a well known value, called urn
allocation and is the limiting allocation of some designs like DTL and PTW. As stated in
the introduction, this value represents the relative risk of failure.
After presenting and studying the properties of the three scenarios, we compare them
with their inspiring rules, to check their goodness. We have done a simulation study com-
paring scenarios S1, S2 and S3 with the RRU, PTW and DTL rules. Based on the previous
theory, we know the almost sure convergence of the process of treatment 1 assignments,
{Nn,1}. We have simulated for each design 1000 replications of a trial with 200 patients.
We have plotted the number of allocations in treatment 1, to see the performance of the
design, and also we have checked the convergence to get an idea of the variance of this
process under the different rules. The results vary with different success probabilities, we
have chosen some pairs of probabilities that summarize the overall behavior.
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Figure 2.3: Comparison of the three scenarios presented (S1, S2, S3) with their inspiring
designs, RRU, PTW and DTL. 1000 replications of the trial for 200 patients and success
probabilities p1 = 0.9, p2 = 0.8 and p1 = 0.9, p2 = 0.5
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Figure 2.4: Comparison of the three scenarios presented (S1, S2, S3) with their inspiring
designs, RRU, PTW and DTL. 1000 replications of the trial for 200 patients and success
probabilities p1 = 0.7 and p2 = 0.4
Observing the figures, we can get a good idea about the performance of the three
scenarios. In S1 and S2, the rule allocates most of the patients to the best treatment than
their inspiring rules, so we can say that they are more ethical. Nevertheless, we can see a
lot of variance and many extreme cases. For S3, we can observe that the behavior is very
similar to the DTL rule. We already know that the limit of the proportion of allocations in
treatment 1 is the same, but the similarity of the box suggests a similarity in the variance.
As the DTL rule has been proven competitive, we have evidence that S3 could have good
properties, so we have to confirm it theoretically.
The next table is built in the spirit of the tables of [62], comparing an ethical measure
and an inferential one. n represents the number of patients that generate a simulated
power of 90% for the test pˆn,1−pˆn,2−(p1−p2)√ p1q1
Nn,1
+
p2q2
Nn,2
when the complete randomization design is
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applied. Then, the simulated power and the mean number of failures (with the standard
deviation between round brackets) are obtained for the S1, S2 and S3 designs and their
classical related rules. Observe that the expected number of failures for the S3 design is
exactly obtained from.
Table 2.1: Simulated power and expected number of failures (standard deviation). 5.000
replications.
RRU S1
p1 p2 n Power Failures Power Failures
0.9 0.8 532 83 75 (12.4) 17 75 (26.1)
0.9 0.5 48 80 12 (3.9) 52 9 (4.9)
0.7 0.4 108 82 43 (6.6) 41 39 (9.4)
PTW S2
p1 p2 n Power Failures Power Failures
0.9 0.8 532 87 75 (8.9) 20 68 (22.9)
0.9 0.5 48 84 11 (3.1) 39 7.4 (2.9)
0.7 0.4 108 88 45 (5.6) 43 36 (5.7)
DTL S3
p1 p2 n Power Failures Power Failures
0.9 0.8 532 89 73 (7.9) 89 72.04
0.9 0.5 48 86 11 (2.6) 87 11.41
0.7 0.4 108 87 44 (5.4) 87 44.30
Note that S1 and S2 designs are competitive with, or slightly better than their related
rules, RRU and PTW, from the point of view of the number of failures, but clearly inferior
from the point of view of the power of the test statistic. This loss of power could be foreseen
from the previous comparative graphic. In that graphic, we could observe that S1 and S2
have greater variance in the number of allocations to treatment 1. From the results in [32],
the higher the variability of Nn,1 the smaller is the power of the test statistic, as is clearly
seen in the table. On the other hand, S3 is again confirmed as a rule very similar to the
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DTL rule, with almost similar values in both measures, power and expected number of
failures.
In summary, we have presented three new response-adaptive designs, inspired in three
already well known designs. Although they have a good ethical behavior, we can confirm
that S1 and S2 are not adequate as clinical trials, due to their very bad inferential prop-
erties, low power and very high variability in the number of allocations. As the DTL rule
is perceived as a competitive response-adaptive design, the S3 scenario seems promising
and a deeper theoretical study appears necessary.
2.2 Klein urn design
S3 design was already presented in [41], like a stochastic process for physics applications
and not like a clinical trial design. The urn model will be called Klein urn model in the
sequel and the design, Klein urn design or Klein design. The procedure of the design is as
follows. Patients arrive sequentially and their responses to treatments are known before
the arrival of the next patient. For each patient, a ball is drawn. If the ball is of type 1,
the patient receives treatment 1; otherwise, it receives treatment 2. If the treatment is
successful, the ball is replaced in the urn; otherwise, the ball extracted is removed and a
ball of the other type is added to the urn. Therefore, the number of balls of type 1 in the
urn after the n-th replacement, Wn,1, increases one step if a treatment of type 2 is applied
and it is a failure and decreases one step if treatment type 1 is applied and it is a failure;
otherwise, the number of type 1 balls in the urn remains unchanged. Then, as was stated
before, the evolution of the number of balls of type 1 in the urn, {Wn,1}, is a Markov chain
with state space E = {0, ..., 2w} and the following transition matrix P = (pi,j),
pi,j =

q2(1− i2w ), j = i+ 1;
p1
i
2w + p2(1− i2w ), j = i;
q1
i
2w , j = i− 1;
0, otherwise,
i = 0, . . . , 2w. (2.16)
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In the first section we have made a study of the processes associated to the urn design,
like {Wn,1} and {Nn,1}, for the three scenarios. In this section, as we are focused on the
Klein urn, we are able to extend these results.
Following the notation presented in Chapter 1, let Fn be the natural σ-algebra of the
design, with the past allocations and responses. Formally, Fn = σ(Gn,Zn), being Gn the
set of allocations until the n-th patient and Zn the set of observed responses until the
n-th patient. We also define Rn as the random variable determining the number of balls
of type 1 added to the urn in the n-th step, which can be decomposed like
Rn = Zn,1(1− δn)− Zn,2δn. (2.17)
Note that
Wn = Wn−1 +Rn. (2.18)
Taking expectations in (2.17),
E[Rn] = q2 (1− E[δn])− q1E[δn]
From the allocation rule of the Klein urn design, the probability of assigning one treatment
is the proportion of balls of this treatment in the urn. Using this we can derive E[δn] =
E[E[δn|Fn−1]] = E[E[δn|Wn−1,1]] = E[Wn,1/2w], so we have
E[Rn] = q2(1− E[Wn−1,1]/(2w))− q1E[Wn−1,1]/(2w). (2.19)
Squaring (2.17) and taking expectations, we get a similar expression for E[R2n],
E[R2n] = q2(1− E[Wn−1,1]/(2w)) + q1E[Wn−1,1]/(2w). (2.20)
To alleviate the notation, in what follows we denote r = 1−((q1 +q2)/(2w)), s = 2r−1
and µN = q2/(q1 +q2). Note that (w−1)/w < r < 1, (w−2)/w < s < 1 and µW = 2wµN .
We assume, without loss of generality, that q1 ≤ q2. Then µW ≥ w, so the urn has in the
limit more balls of the best treatment, if q1 6= q2.
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Proposition 2.2.1. Assume that the Klein urn design is applied and W0,1 is a generic
random variable. Then,
a)
E[Wn,1] = µW + rnd0
where d0 = (E[W0,1]− µW ),
b)
V ar[Wn,1] =
2wq1q2
(q1 + q2)2
(1− sn) + d0 (q1 − q2)
q1 + q2
(sn − rn) + d20(sn − r2n)
+ snV ar[W0,1] .
Proof. The a) part is proven in Remark 2.1.4, now considering the most generic case of
W0,1 as a general random variable. For the variance we observe that, from (2.18),
V ar[Wn,1] = V ar[Wn−1,1] + V ar[Rn] + 2Cov(Wn−1,1, Rn).
From (2.17), we have that
Cov(Wn−1,1, Rn) = E[Wn−1,1Zn,2]− E[Wn−1,1(Zn,1 + Zn,2)δn]− E[Wn−1,1]E[Rn]
Using the independence of the responses and (2.20),
Cov(Wn−1,1, Rn) =
= q2E[Wn−1,1]− q1 + q22w E[W
2
n−1,1]− q2E[Wn−1,1] +
q1 + q2
2w
E2[Wn−1,1]
= − q1 + q2
2w
(E2[Wn−1,1]− E[W 2n−1,1]) = (r − 1)V ar[Wn−1,1]. (2.21)
Therefore
V ar[Wn,1] = sV ar[Wn−1,1] + V ar[Rn],
and solving the recurrence,
V ar[Wn,1] =
n∑
k=1
sn−kV ar[Rk] + snV ar[W0,1]. (2.22)
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So that {V ar[Wn,1]/sn} increases with n. Moreover, combining (2.19) and (2.20) we have
that,
V ar[Rk] = q2 − q22 +
[
q1 − q2 + 2q2(q1 + q2)
2w
]
E[Wk−1,1]−
[
(q1 + q2)
2w
]2
E2[Wk−1,1]
From (a), we know that E[Wk−1,1] = µW + rk−1d0, so we get
V ar[Rk] =
2q1q2
q1 + q2
+
d0
2w
rk−1
[
(q1 − q2)− d02w (q1 + q2)
2rk−1
]
(2.23)
Putting (2.23) in (2.22), b) follows.
Remark 2.2.1. From the expression of Proposition 2.2.1 a), we can easily see the mono-
tone convergence of {E[Wn,1]} to µW . As {Wn,1} is a Markov chain, this convergence is
exponential which is also easily identifiable due to the appearance of a geometric progres-
sion with |r| < 1. Besides this, if E[W0,1] > µW , the sequence is strictly decreasing and if
E[W0,1] < µW the sequence is strictly increasing.
We have already seen the strong relationship between the treatment 1 allocation in-
dicator, δn, and the number of balls of type 1 in the urn in the previous step, Wn−1,1.
Using this relationship we get the next corollary, which gives exact results for each n for
the {δn} process.
Corollary 2.2.1. Assume that the Klein urn design is applied and W0,1 is a random
variable taking values in E. Then,
a)
E[δn] = µN + rn−1
(
d0
2w
)
b)
V ar[δn] =
(
µN + rn−1
d0
2w
)(
1− µN − rn−1 d02w
)
Proof. Observe that
E[δn] = E[E[δn|Fn−1]] = E[E[δn|Wn−1,1]] = E[Wn−1,1]2w (2.24)
for n ≥ 1, and therefore, a) and b) follow straightforwardly, using the a) result from
Proposition 2.2.1.
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The following result is a technical lemma, which is going to be useful during the proofs
of this chapter and which connects the variance of variables with the covariances of their
conditional expectation.
Lemma 2.2.1. If X and Y are random variables and X is F-measurable, then
Cov(X,Y ) = Cov(X,E[Y |F ])
Proof.
Cov(X,E[Y |F ]) = E[XE[Y |F ]]− E[X]E[E[Y |F ]]
= E[E[XY |F ]]− E[X]E[Y ] = Cov(X,Y )
Let δn = (δ1, δ2, . . . , δn) be the vector of indicator variables of type 1 treatment. The
components of the covariance matrix of δn, Σδn , can be expressed in terms of known
processes as follows.
Proposition 2.2.2. Assume that the Klein urn design is applied. The components of the
covariance matrix of δn satisfy the following relations
Cov(δi, δj) =

V ar[δi], i = j;
1
4w2
V ar[Wi−1,1] + (r − 1)V ar[δi], j = i+ 1;
rj−i−1Cov(δi, δi+1), j > i+ 1.
Proof. Consider first that j > i + 1, with i = 1, . . . , n. From Lemma 2.2.1 and (2.24) we
have
Cov(δi, δj) = Cov(δi, E[δj |Wj−1,1])
=
1
2w
(E[δiWj−1,1]− E[δi]E[Wj−1,1]) .
Using the recursive relation (2.18),
Cov(δi, δj) =
1
2w
(E[δiWj−2,1] + E[δiRj−1]− E[δi]E[Wj−2,1]− E[δi]E[Rj−1])
= Cov(δi, δj−1) +
1
2w
Cov(δi, Rj−1) . (2.25)
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As the response of the patients is independent of the previous history of allocations
and responses, from the definition of Rj−1, Rj−1 = Zj−1,1(1− δj−1)−Zj−1,2δj−1, we have
Cov(δi, Rj−1) = −(q2 + q1)Cov(δi, δj−1)
and plugging this result in (2.25), we finally have
Cov(δi, δj) = rCov(δi, δj−1). (2.26)
Developing the recurrence, we get the result,
Cov(δi, δj) = rj−i−1Cov(δi, δi+1).
For the case of j = i+ 1, proceeding as in (2.25) - (2.26) we obtain
Cov(δi, δi+1) =
1
2w
(E[δiWi−1,1]− E[δi]E[Wi−1,1])− (1− r)V ar[δi]
=
1
4w2
V ar[Wi−1,1] + (r − 1)V ar[δi]
and the result follows.
The previous results were focused on the number of type 1 balls in the urn, Wn,1, and
the treatment 1 allocation indicators, δn. Another relevant process in a clinical trial is
the number of allocations to treatment 1 until the n-th patient, Nn,1. Obviously, Nn,1 =∑n
i=1 δi. Using this relation and (2.24), we can obtain exact and asymptotic results for
this process.
Proposition 2.2.3. Assume that the Klein urn design is applied. For each n > 0, we
have
a)
E [Nn,1] = nµN +
(1− rn)
(1− r)
(
E[W0,1]
2w
− µN
)
. (2.27)
b)
V ar[Nn,1] =
n∑
i=1
V ar[δi] +
2
1− r
n−1∑
i=1
(
(1− rn−i)Cov(δi, δi+1)
)
. (2.28)
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Proof. In Remark (2.1.4) a) has been proven. To prove b), observe that
V ar[Nn,1] = V ar
[
n∑
i=1
δi
]
= 1tΣδn1,
where 1 is the column vector of ones and 1t is its transpose. From Proposition 2.2.2, b)
follows straightforwardly.
A strong law and a central limit theorem can be obtained for the allocation process
{Nn,1}.
Proposition 2.2.4. Let {Nn,1} be the allocation process of treatment 1 when the Klein
urn design is applied. Then,
a)
Nn,1
n
→ µN , a.s.
b)
√
n
(
Nn,1
n
− µN
)
→ N(0, σ2N )
where σ2N =
q1q2(p1 + p2)
(q1 + q2)3
.
Proof. Note that E[δn|Fn−1] = Wn−1,1/2w. We can build a martingale {Mn} such that
Mn =
n∑
k=1
(δk − E[δn|Fn−1]) =
n∑
k=1
(
δk − Wk−1,12w
)
and {(1/2w)∑n−1k=0 Wk,1} is the compensator of the allocation process {Nn,1}. As the
Markov chain {Wn,1} is ergodic, we are in the conditions of Theorem 1 in [6]. Therefore,
we have that a) follows and
√
n(Nn,1n −µN ) converges in distribution to a random variable
with normal distribution and zero mean. We only need to obtain the variance of this limit
distribution. That is, we have to calculate limn→∞V ar[Nn,1]/n.
Proposition 2.2.3, b) gives an explicit expression of V ar[Nn,1],
V ar[Nn,1] =
n∑
i=1
V ar[δi] +
2
1− r
n−1∑
i=1
(
(1− rn−i)Cov(δi, δi+1)
)
.
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The expression is in terms of V ar[δn] and Cov(δn, δn+1), so we only need the limits of
these quantities. From Proposition 2.2.1 and the fact that the stationary distribution of
{Wn,1} is binomial, we have
V ar[δn]→ q1q2(q1 + q2)2 .
From Proposition 2.2.2 we have
Cov(δn, δn+1) =
1
4w2
V ar[Wn−1,1] + (r − 1)V ar[δn],
and taking limits,
Cov(δn, δn+1)→ 12ω
q1q2
(q1 + q2)2
+ (r − 1) q1q2
(q1 + q2)2
.
Then, applying Toeplitz lemma in the expression of V ar[Nn,1]/n, b) follows.
Remark 2.2.2. It is worth highlighting that these asymptotic limits are the same as
those obtained when the drop-the-loser rule is applied. The proportion of allocations to
treatment 1 up to the n-th patient, Nn,1/n, converges to q2q1+q2 , the urn allocation, in
both designs. In the central limit theorem, the asymptotic variance is also the same,
σ2N =
q1q2(p1 + p2)
(q1 + q2)3
, which is the minimum variance that could be reached with the urn
limit allocation, as was shown in [34].
Remark 2.2.3. In order to obtain the asymptotic variance σ2W in (2.6), reasoning as in
Proposition 2.2.4, we solve limn→∞ V ar[
∑n
k=1Wk,1]/n. We decompose the variance
V ar
[
n∑
k=1
Wk,1
]
=
n∑
k=1
V ar[Wk,1] + 2
∑
k>j
Cov(Wk,1,Wj,1)
We know that Wk,1 = Wk−1,1 +Rk, so, for each k > j, combining (2.17) and Lemma 2.2.1,
we get
Cov(Wk,1,Wj,1) = Cov(Wk−1,1 +Rk,Wj,1) = rk−jV ar(Wj,1).
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If we introduce this recurrence in the previous sum,
V ar
[
n∑
k=1
Wk,1
]
=
n∑
k=1
V ar[Wk,1] + 2
n∑
j=1
rk−jV ar[Wj,1]
=
n∑
k=1
V ar[Wk,1] + 2
n∑
j=1
n∑
k=j+1
rk−jV ar[Wj,1]
=
n∑
k=1
V ar[Wk,1] +
2r
1− r
n∑
j=1
V ar[Wj,1](1− rn−j).
From Proposition 2.2.1 b) we have a closed expression for V ar[Wk,1]. So, taking limits in
V ar[
∑n
k=1Wk,1]/n, we have σ
2
W = 4w
2σ2N (1 + r)/(p1 + p2).
Corollary 2.2.2. Assume that the Klein urn design is applied and q1, q2 ∈ (0, 1) with
q1 6= q2. Then, there exists a value i0 ≥ 2 such that, for any pair of indices j > i > i0,
a) If q1 + q2 > 1, then Cov(δi, δj) < 0.
b) If q1 + q2 < 1, then Cov(δi, δj) > 0.
Proof. Without loss of generality, let us assume that q2 > q1. As q1, q2 ∈ (0, 1), V ar[δi] >
0, for any i ≥ 2. From Proposition 2.2.2 we have that Cov(δi, δi+1) and Cov(δi, δj) with
j > i have the same sign, and they are positive when
V ar[Wi−1,1]
V ar[δi]
> 2w(q1 + q2). (2.29)
As the sequence
{
V ar[Wi−1,1]
V ar[δi]
}
converges to 2w, when i→∞, from (2.29) we get a)
and b).
Remark 2.2.4. If q1 = q2 = q and W0,1 = w, then, d0 = 0 and V ar[W0,1] = 0 in
Proposition 2.2.1 b). Therefore, V ar[Wi,1] = w(1− si)/2 and V ar[δi] = 1/4, so that, the
sequence {V ar[Wi−1,1]/V ar[δi]} becomes {2w(1 − si−1)}. For any w ≥ 2, this sequence
strictly increases to 2w. Therefore, if q > 1/2, Cov(δi, δj) < 0 for any i < j. If q < 1/2, the
sequence {V ar[Wi−1,1]/V ar[δi]} will eventually be greater than 2w2q, and therefore, there
exists i0, namely i0 = log(1− 2q)/log(s), such that, Cov(δi, δj) > 0 for any i0 < i < j. If
i0 is a positive integer, then Cov(δi0 , δj) = 0, for any j > i0.
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2.3 Performance of the Klein design
In the previous section a probabilistic analysis of the different processes associated to the
urn has been made when the Klein has been applied for the allocations. Now, we present
different properties about the performance of the design, focusing more on a practical
aspect. As we have presented a new design, we should compare it with other designs in
the literature and study its performance properties.
In this section we obtain explicit formulae for the main operating characteristics of the
Klein design, such as the expected treatment failures, power with the Wald test, selection
bias and accidental bias. As we have seen, the Klein design and the DTL design have the
same limit allocation and the same asymptotic variance in the proportion of allocations. So
that, a similar behavior for their operating characteristics should be expected. However,
the Klein design has an important advantage which is that, for each n, exact formulae
have been obtained for the expectation and the variance of the number of patients in each
treatment.
2.3.1 Expected number of failures and power
In the specialized literature, some comparative studies have been made among outstand-
ing response-adaptive designs in order to establish a preference for a particular procedure
according to their degree of compromise among ethics, randomness and inferential accu-
racy. As mentioned in Chapter 1, the DBCD2 design and the DTL design have been found
competitive due to their good operating characteristics, see, for instance, [62] and [24].
In [62] the power of the usual Wald test and the expected number of failures are
obtained, via simulation, for the DTL design (Table 2) and for the DBCD2 design (Table
3), for the number of patients, n, that provide a power of 90% for the complete randomized
design. Using the previous notation, the expected number of failures can be expressed as
follows,
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E
[
n∑
i=1
(δiZn,1 + (1− δi)Zn,2)
]
= (q1 − q2)E[Nn,1] + nq2,
and we can obtain, using Proposition 2.2.3, this expected value for any initial state W0,1.
Proposition 2.2.3 implies that Nn,1 → ∞ and Nn,2 → ∞ when the Klein design is
applied. Then, the conditions of Theorem 1 in [11] are fulfilled, and a central limit theorem
holds for the proportion of successes of each treatment. Therefore, the Wald test can
be used for large sample sizes. These results are reproduced in our Table 2.2 in order
to compare them with the expected number of failures for the Klein design (which is
calculated assuming that W0,1 = w, and the power, obtained for the Klein design in the
same simulation conditions, that is, 10,000 replications (α = 0.05, two-sided). Negligible
differences appear between the behavior of the DTL and the Klein design, so that Klein
design would be preferred to the DBCD2 design in the same situations in which the DTL
rule would be preferred.
Note also that the power of the usual Wald test when the Klein design is used is similar
to the power when the DTL design is used, and it is within 1% of complete randomization.
Table 2.2: Simulated expected number of failures (standard deviation) for the DBCD2 and
DTL designs, exact values for the Klein design, and simulated power (10,000 replications).
DBCD2 DTL Klein
p1 p2 n Power Failures Power Failures Power Failures
0.9 0.3 24 91 8 (1.7) 90 7 (1.8) 90 7.71
0.9 0.5 50 91 13 (2.6) 89 12 (2.6) 88 11.81
0.9 0.7 162 90 31 (4.8) 89 27 (4.6) 88 26.71
0.9 0.8 532 91 79 (8) 89 73 (8) 89 72.04
0.7 0.3 62 90 28 (3.5) 89 27 (4.1) 89 27.57
0.7 0.5 248 90 97 (7.5) 89 93 (8.0) 89 93.62
0.5 0.4 1036 90 567 (16) 89 565 (16) 90 565.17
0.3 0.1 158 90 122 (5.4) 90 124 (5.3) 89 124.58
0.2 0.1 532 90 448 (9) 90 451 (8) 90 450.67
50
2.3.2 Selection Bias
One of the main advantages of the use of random allocation rules in the assignment of
patients is the impossibility to accurately guess the treatment that is going to be applied
to the next patient. Even so, in unmasked clinical trials and due to the sequential arrival of
patients, the researcher could have a guess of which treatment is more likely to be assigned
and this could consciously or unconsciously affect the recruitment process and bias the
study. Therefore, a natural way to reduce selection bias is to increase the randomness of
the design, avoiding deterministic or skewed allocations. For instance, the best allocation
rule in terms of randomness is complete randomization, because all the allocations have
probability equal to 1/2. As we move away from this probability, randomness is lost and
the design is more vulnerable to selection bias. In response-adaptive designs, the allocation
probabilities are skewed because this is one of the goals of the design, but we can still think
about selection bias.
In [12], a measure of randomness is presented, which is based on the in mean distance
between the proportion of guesses of the next treatment to be applied, with an optimal
guessing strategy, and the maximum uncertainty, which is equal probability. We present
a measure based on that, called average selection bias. Let Jk be the indicator variable
of the event “correct guess of the treatment applied to the kth patient”. Observe that
the best strategy is to predict the treatment with more balls in the urn. Therefore,
E[Jk] = E[max(Wk−1,1, 2w −Wk−1,1)]/(2w) = (w + E[|Wk−1,1 − w|])/(2w). We consider
the average selection bias up to the epoch n given by
βn :=
1
n
n∑
k=1
E[Jk]
=
1
2
+
1
2wn
n∑
k=1
E[|Wk−1,1 − w|]
=
1
2
+
1
2wn
n∑
k=1
(
w∑
i=1
i(P (Wn,1 = w + i) + P (Wn,1 = w − i))
)
. (2.30)
Using that the stationary distribution of {Wn,1} for the Klein urn model is binomial
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with parameters 2w and q2/(q1 + q2), we have from (2.30) that
βn → β∞ := 12 +
1
2w
(
l
(l + 1)2
)w w∑
i=1
i
(
2w
w + i
)
(li + l−i) (2.31)
where l = q2/q1.
Remark 2.3.1. Note that β∞ does not change if we define l = q1/q2. This expression is
related with the absolute deviation of the binomial distribution (see [40] for a wider study
about absolute deviations) and it can be expressed, using the Gaussian hypergeometric
function, as
β∞ =
1
l + 1
+
1
w
(
2w
w + 1
)
lw+1
(l + 1)2w 2
F1(2, 1− w,w + 2,−l) .
In Table 2.3 the average selection bias of the Klein design is presented, βn, for some
combinations of values q1 and q2, and for n = 50, 200. These quantities are calculated
assuming that W0,1 = w, and using formula (2.30), where the exact values of the n-step
probabilities are those given in [41]. This table also provides the average and standard
deviation of βn for the DTL and DBCD2 designs, obtained by simulation (10,000 replica-
tions). Again, the DTL and the Klein design perform in a quite similar way. We observe
that the biased coin design (DBCD2 design) is less predictable for small ratios l .
Table 2.3: Average selection bias (s.d.) for DTL and DBCD2 designs (10.000 replications),
exact values for the Klein design.
DTL DBCD2 Klein
l q1 q2 50 200 50 200 50 200 ∞
1 0.2 0.2 0.58(0.07) 0.59(0.04) 0.68(0.08) 0.63(0.04) 0.56 0.58 0.588
1 0.6 0.6 0.64(0.06) 0.64(0.03) 0.55(0.07) 0.54(0.04) 0.58 0.59 0.588
0.7 0.35 0.5 0.63(0.06) 0.64(0.03) 0.6(0.08) 0.59(0.05) 0.59 0.61 0.614
0.5 0.25 0.5 0.65(0.06) 0.67(0.03) 0.64(0.09) 0.66(0.06) 0.61 0.65 0.672
0.3 0.15 0.5 0.67(0.07) 0.73(0.04) 0.61(0.07) 0.62(0.05) 0.64 0.73 0.769
2.3.3 Accidental Bias
When a clinical trial is planned, the covariates that could influence in the outcome of the
patient are included in the design and in the allocation rule. However, it is impossible to
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predict all the possible effects in the patients with accuracy, so, sometimes, there could
be some important covariates that have not been taken into account. Accidental bias is
defined as the effect of a covariable that has not been taken into account and which has
influence on the response. An imbalance in those covariates could produce a bias in the
treatment effect estimation. The randomization process by itself mitigates this problem,
but in asymptotic terms. In small samples there could be large imbalances.
On the other hand, the approach to accidental bias is different in treatment-adaptive
designs and response-adaptive designs. Treatment-adaptive designs pursue balance be-
tween the two treatments, and also, a balance in the covariables is desirable. In response-
adaptive designs, the limit of the allocations is skewed to the best treatment, so the same
distribution of covariate levels among treatmens is pursued.
One natural wish is that the covariate effect is similar in the two treatments, so a way
to measure the accidental bias could be the unbalance of the covariate effect between the
two treatments. If we denote the covariate as a random variable H, a measure of covariate
unbalance (see [63]) could be
∆Fn =
n∑
i=1
δiHi
Nn,1
−
n∑
i=1
(1− δi)Hi
Nn,2
,
where Hi is the value of covariate H in the i-th patient. If we assume that {Hi} is a
sequence of independent and identically distributed random variables with variance σ2,
then
E[∆Fn] = 0 and V ar[∆Fn] =
σ2
n
E
[
n2
Nn,1(n−Nn,1)
]
.
If the expectation E
[
n2
Nn,1(n−Nn1,)
]
is uniformly bounded by a constant, we can use
the Markov property, and we have that, for any value ε > 0,
P (|∆Fn| > ε)→ 0, when n→∞ . (2.32)
A different approach is possible. As we have seen, the conditions of Theorem 1 in
[11] are fulfilled for the Klein design. Then, we have a strong law for
∑n
i=1 δiFi/Nn,1 and
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∑n
i=1(1− δi)Fi/Nn,2. Therefore, ∆Fn → 0 a.s. and, in particular, (2.32) holds.
In order to evaluate the speed of convergence, we simulate the probability of unbalance
for the Klein design, the DTL design and the DBCD2 design. Results are presented in
Table 2.4. We take n = 50, 200, 1000 and (p1, p2) = (0.8, 0.8), (0.8, 0.5), (0.8, 0.2). The
sequence {Fi} are independent Bernoulli random variables with success probability 0.3.
The average of the proportion of trials with the standard deviation between brackets, in
1000 sets of 1000 replications of the trial, for which |∆Fn| > 0.1 is computed for each
combination of size and success probabilities. We see that, in spite of the convergence to
0, the probability of unbalance is not negligible for small values of n. Observe that the
Klein design has slightly smaller values for the measure of covariate imbalance.
Table 2.4: Simulation of P (|∆Fn| > ε), ε = 0.1, average of the frequency (standard
deviation below) for DTL, DBCD2 and Klein designs (1000 sets of 1000 replications of
the design).
n 50 200 1000
p1, p2 DTL DBCD2 Klein DTL DBCD2 Klein DTL DBCD2 Klein
0.8, 0.8
0.450 0.463 0.445 0.125 0.127 0.125 0.0005 0.0006 0.0006
(0.039) (0.040) (0.040) (0.016) (0.017) (0.016) (0.0007) (0.0008) (0.0008)
0.8, 0.5
0.498 0.493 0.458 0.166 0.166 0.1539 0.0018 0.0019 0.0017
(0.036) (0.038) (0.039) (0.018) (0.0183) (0.018) (0.0014) (0.0014) (0.0013)
0.8, 0.2
0.548 0.534 0.484 0.220 0.216 0.197 0.0058 0.0059 0.0052
(0.040) (0.042) (0.036) (0.020) (0.020) (0.020) (0.0025) (0.0026) (0.0024)
The previous approach fails if the independence of the covariate sequence cannot be
guaranteed. A different approach is followed in [19], where a linear model for the response
of each patient, yk, is assumed:
yk = µ+ αδ˜k + βFk + εk, k = 1, . . . , n (2.33)
where δ˜k = 2δk − 1, Fk is the measure of the covariate and εk is the error.
As in [70], we denote uk = βFk + εk, the total error in the mean treatment difference
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when the covariate is not included, then
(2Nn,1(n−Nn,1))−1[n
n∑
k=1
ukδ˜k] . (2.34)
where it is assumed, without loss of generality, that
∑n
k=1 uk = 0. So that, if un =
(u1, . . . , un) and Σδ˜n is the covariance matrix of δ˜n = (δ˜1, . . . , δ˜n), the error variance of
pˆ1 − pˆ2 is proportional to σ2un := u′nΣδ˜nun. The maximum of σ2un is a plausible measure
of the accidental bias (see [19], [70] and [63]). Besides, for each x ∈ Rn
xtΣδ˜nx
xtx
≤ λmax(Σδ˜n) (2.35)
where λmax(A) represents the maximum eigenvalue of the square matrix A. So that, under
the normalization condition
∑n
k=1 u
2
k = 1, we have that σ
2
un ≤ λmax(Σδ˜n), and then the
maximum eigenvalue of Σδ˜n becomes a bound for the accidental bias.
Observe that Σδ˜n = 4Σδn , so that, in what follows, we focus on the study of the
eigenvalues of Σδn . From Proposition 2.2.2 and Corollary 2.2.2 we have a good theoretical
knowledge of the components of this covariance matrix.
The Klein urn model could always be in a stationary regime. It would be sufficient that
the distribution of the initial state W0,1 were binomial with parameters 2w and q2/(q1+q2).
But this is unrealistic, because the probabilities q1 and q2 are unknown. Nevertheless, as
it was done in [19] for the Efron design, we are going to obtain the maximum eigenvalue
for the Klein urn model when it is in stationary regime. Let
ρh := lim
k→∞
Cov(δh, δh+k),
then, from Proposition 2.2.2 we have that
ρk =

q1q2
(q1 + q2)2
, k = 0 ;
rk−1ρ, k ≥ 1 ,
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where ρ =
q1q2(1− (q1 + q2))
2w(q1 + q2)2
. As
∑ |ρk| <∞, the spectral density, f(s), s ∈ [0, pi], is
f(s) =
∞∑
k=−∞
ρke
−isk
= ρ0 + 2ρ
∞∑
k=1
rk−1 cos(sk)
= ρ0 − 2ρ
r
+
2ρ
r
1− r cos(s)
1− 2rcos(s) + r2 , (2.36)
where the last equality follows from exercise 189 of chapter XII in [42]. Besides, we have
f(0) = σ2N f(pi) = ρ0
(
4w − (p1 + p2)
4w − (q1 + q2)
)
.
From the analysis of the derivative of f(s) we have that, in the stationary regime,
a) If q1 + q2 < 1, f(s) is strictly decreasing. Then σ2N is an upper bound for the
maximum eigenvalue.
b) If q1 + q2 = 1, f(s) = ρ0 for any value s. Then ρ0 is the maximum eigenvalue.
c) If q1 + q2 > 1, f(s) is strictly increasing. Then f(pi) is an upper bound for the
maximum eigenvalue.
These conditions can be seen as a hint of what happens in the general case.
Remark 2.3.2. A bound that is valid for the stationary case might not be valid in
general. This is the case in the Efron design, for which the maximum eigenvalue in the
stationary analysis is smaller than the value of the left hand side in (2.35) when n = 2
and xt = (1/
√
2,−1/√2), as stated in [70]. This problem has been revisited in [46] where
they conjecture that the maximum eigenvalue of the covariance matrix does not depend
on n.
Intensive numerical calculations, suggest that the following conjecture, which has been
proven in the stationary case, is also valid in the general case:
Conjecture: When q1+q2 < 1, the maximum eigenvalue grows with n towards σ2N given
in Proposition 4. Otherwise, it grows with n towards a constant value a := a(p1, p2, w)
for which a closed form expression has not been found.
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Table 2.5: Maximum eigenvalue of covariance matrix, Σδn , for different values of n and
probability pairs
q1 q2 100 500 1000 2000 ∞
0.1 0.3 0.340713 0.693317 0.735494 0.746441 f(0)=0.75
0.1 0.5 0.257493 0.313943 0.321786 0.323538 f(0)=0.324074
0.3 0.5 0.304317 0.348628 0.350836 0.351383 f(0)=0.351562
0.3 0.7 0.261711 0.261711 0.261711 0.261711
0.5 0.7 0.263667 0.263667 0.263667 0.263667
Chapter 3
Exact Randomization Based
Inference
As stated in Chapter 1, the procedure to recruit patients in a clinical trial may not be
a random sampling and, so, there is no formal basis to accept the population model. In
this context, the randomization procedure gives us a basis for inference by means of a
randomization test. The null hypothesis of a randomization test is that the two treat-
ments are equivalent, so the assignment process does not affect the patients’ responses
and these responses are considered fixed. The way to compute a p-value with a random-
ization test is to sum the probabilities of the treatment allocation permutations which
lead to a value of the test statistic more extreme than the experimental one. This exact
calculation requires the enumeration of all the permutations and computing the probabil-
ity for each one, consistent with the allocation rule and the set of responses, which can be
computationally unfeasible or very time consuming. In order to avoid all the enumeration,
shorten the calculations and make the problem solvable, three ways have been presented
in the specialized literature: the asymptotic distribution of the test statistic, Monte Carlo
estimations of the p-values, and computational algorithms. In this chapter a recurrence
algorithm to compute the exact distribution of two test statistics is presented, valid for a
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wide family of response-adaptive designs, which is named < family. Some designs in the
literature that are included in the family are presented. With such designs, a simulation
study is done, comparing different methods to obtain p-values and using these methods
to make a power study. Finally, the algorithm is adapted to the DTL design, which is not
in the < family.
3.1 Exact Randomization Based Inference (RBI) for response-
adaptive designs
Let Yn be the response of the n-th patient and let An = {Y1 = a1, Y2 = a2, . . . , Yn = an}
be the set of responses of the first n patients. These responses are binary and assuming the
randomization model, deterministic. Thus, all the processes in this chapter are conditioned
to the particular set An. As the responses are dichotomous, ai = 1 in case of success and
ai = 0 in case of failure. So, being the responses deterministic, the only random process
is the allocation process, {δ˜i}, which is the sequence of centered allocation indicators.
Let δ˜n = 1, if the patient is allocated in treatment 1, and δ˜n = −1 if it is allocated in
treatment 2. It can be linked with the usual indicators through the linear transformation
δ˜n = 2δn − 1. In what follows, it is assumed that patients are randomized between
treatments following a response-adaptive design, then the allocation process, {δ˜n}, depends
on the past allocations and on the past deterministic responses.
The choice of a suitable test statistic is fundamental in any inferential procedure. Most
of the nonparametric tests use linear rank tests and in the case of permutation tests, this
is the usual procedure. In our case, we are going to consider a version of a linear rank test
statistic for binary responses. Consider now the test-statistic
Sn =
n∑
i=1
aiδ˜i , (3.1)
which represents the difference between successes and failures in both treatments. Sn
is the randomization test statistic for studying the equality of treatments. This choice
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responds to the arguments given in section 2.5 in [56], where test statistics based on sum
of responses are advised.
As stated in section 1.3, unconditional and conditional randomization tests are consid-
ered. The former implies that, given a number of patients n and a significance level α, the
null hypothesis is rejected when the experiment gives a value s for the statistic Sn such
that P (|Sn| > s) < α. The latter behaves in a similar way but if the experiment has an
imbalance in the number of patients ∆n = Nn,1−Nn,2 = t patients, the null hypothesis is
rejected when P (|Sn| > s|∆n = t) < α.
The exact distribution of the test Sn is unknown and it must be computed enumerating
all the possible permutations and calculating the probability of each arrangement. But
the number of permutations increases very fast and even for moderate sizes of n it is
computationally unfeasible. In [31] and [50] several algorithms to avoid all the calculations
were presented, valid for a family of non response-adaptive designs. Here, we present
a recursive algorithm to compute the exact distribution of the statistic Sn in a quite
general framework. Our target now is to obtain an algorithm for finding the exact value
of P (Sn = s) for any value s in the interval [−n, n].
Observe that
P (Sn = s) =
n∑
i=−n
P (Sn = s, ∆n = i) (3.2)
P (∆n = t) =
n∑
k=−n
P (Sn = k, ∆n = t)
and therefore, if P (∆n = t) > 0,
P (Sn = s|∆n = t) = P (Sn = s, ∆n = t)
P (∆n = t)
, (3.3)
so that, in order to obtain the exact distribution for Sn via recurrence equations, in both
cases, unconditional and conditional, is enough if a recurrence for P (Sn = s, ∆n = t) is
obtained. Besides this, this is also enough to obtain exact values for other test statistics
that are transformations of the Sn test statistic.
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Once the recurrence relation is stated, we are going to define the family of response-
adaptive designs <, for which the algorithm is applicable. < is the family of response-
adaptive designs such that there exists a sequence of functions {hn} on R3 such that for
each n
hn(s, l) = P (δ˜n = 1|Sn−1 = s, ∆n−1 = l),
namely, the probability distribution of δ˜n is completely determined by the values of Sn
and ∆n in the previous step.
The following proposition provides a recursion which will make computationally feasi-
ble to obtain the exact p-value for the Sn statistic when patients are randomized between
treatments with a response-adaptive design of the family <.
Proposition 3.1.1. Assume that n patients are allocated with a response-adaptive design
in the family <. Then,
P (Sn = s, ∆n = t) = hn(s− an, t− 1)P (Sn−1 = s− an, ∆n−1 = t− 1) +
+ (1− hn(s+ an, t+ 1))P (Sn−1 = s+ an, ∆n−1 = t+ 1)
with initial values for a = 1, 0, −1 and b = 1, −1
P (S1 = a, ∆1 = b) = ((1− a1)(1− |a|) + |a|a1(1 + a ∗ b)/2)P (δ˜n = b).
Proof. Observe that
P (Sn = s, ∆n = t) = P (Sn−1 + anδ˜n = s, ∆n−1 + δ˜n = t)
= P (Sn−1 + anδ˜n = s, ∆n−1 + δ˜n = t, δ˜n = 1)
+P (Sn−1 + anδ˜n = s, ∆n−1 + δ˜n = t, δ˜n = −1) . (3.4)
As
P (Sn−1 + anδ˜n = s, ∆n−1 + δ˜n = t, δ˜n = 1)
= P (δ˜n = 1|Sn−1 = s− an,∆n−1 = t− 1)P (Sn−1 = s− an, ∆n−1 = t− 1)
61
and
P (Sn−1 + anδ˜n = s, ∆n−1 + δ˜n = t, δ˜n = −1)
= P (δ˜n = −1|Sn−1 = s+ an,∆n−1 = t+ 1)P (Sn−1 = s+ an, ∆n−1 = t+ 1),
then, the proposition follows.
Remark 3.1.1. Proposition 6 in section 2.5 of [56] gives a formal argument, based on
asymptotic tools, for choosing a permutation test as an alternative to the classical para-
metric test. Assuming the population model, when a response-adaptive design is used
for allocations, and Sn,i is the total number of successes with treatment i, i = 1, 2, then
(Sn,1, Sn,2, Nn,1) are jointly sufficient for estimating p1 and p2; see p.193 in [63], where
n is the sample size. So a good estimator of p1 − p2 is Sn,1/Nn,1 − Sn,2/Nn,2, where
Nn,2 = n − Nn,1 . Let Tn = Sn,1/Nn,1 − Sn,2/Nn,2 be the difference between success
proportions for each treatment when the n patients have been allocated with a response-
adaptive design and the responses of the n patients, An, are known. Then,
P (Tn = t) =
n∑
k=−n
P (Tn = t, ∆m = k)
=
n∑
k=−n
P (Sn = r(k), ∆n = k)
where r(k) = (t(n2−k2) + 2k∑ni=1 ai)/(2n−k−∑ni=1 ai). Now, using Proposition 1, any
p-value for the distribution of Tn can be obtained.
The statistic Tn is also proposed and discussed in the context of treatment-adaptive
designs in [9]. This proposal relies more on heuristic arguments than on theoretical ones.
3.2 The < family of designs
As stated in the previous section, the family < of response-adaptive designs collects those
used to allocate n patients between two treatments and there exists a sequence of functions
{hn} defined on R2 such that for each n,
hn(s, l) = P (δ˜n = 1|Sn−1 = s, ∆n−1 = l). (3.5)
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There are some useful relationships to link the probability of assigning treatment 1
with the statistics Sn and ∆n. We know that
Sn = Sn,1 − Sn,2 and
n∑
i=1
ai = Sn,1 + Sn,2 , (3.6)
and also
∆n = Nn,1 −Nn,2 and n = Nn,1 +Nn,2 . (3.7)
These relations make it possible to write Sn,1, Sn,2, Nn,1 and Nn,2 in terms of Sn and ∆n,
the condition to be in the < family is not stringent. Many designs in the literature belong
to the family.
The Klein urn design has been presented and thoroughly studied under a population
model in the previous chapter, see section 2.2. It works as follows. Initially, the urn
contains W0,1 balls of type 1, associated to treatment 1, and 2w − W0,1 balls of type
2, associated to treatment 2. W0,1 could be any random variable with values in E =
{0, 1, · · · , w}, but usually we assume that W0,1 = w. When a patient arrives to the
experiment a ball is extracted and receives the corresponding treatment. If the response
of the patient is a success the ball is returned, otherwise, a ball of the other treatment is
added. The total number of balls in the urn remains constant. The number of balls of
type 1 in the urn is a stochastic process denoted by {Wn,1}, n ∈ N.
Proposition 3.2.1. For the Klein design Proposition 3.5 holds with
hn(r, l) =
w + r − l
2w
∀n .
Proof. From the dynamics of the Klein urn design, the probability of assigning treatment
1 is the number of type 1 of balls in the previous step,
P (δ˜n = 1) =
Wn−1
2w
.
The number of type 1 balls decreases in one unit in case of failure in treatment 1 and
increases in one unit in case of failure in treatment 2. So, Wn = w − (Nn,1 − Sn,1) +
(Nn−2 − Sn,2) = w + Sn −∆n and the result follows.
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The next designs in the family are biased coin designs, such as DBCD designs, (1.9)
and ERADE designs, (1.10). In these designs, the allocation rule uses the target allocation
to assign patients. Under the population model, the target allocation depends on the pa-
rameters p1 and p2. Nevertheless, these quantities are unknown, so they are sequentially
estimated, using the classical estimators pˆn1 and pˆn2, and these estimators are used to de-
fine the allocation rule. In the randomization model, the parametric approach disappears,
but these estimators are still used in order to specify the allocation rule and reach a target
allocation, although in fact they are not estimating a parameter. In a philosophical sense,
we can substitute the concept of “estimation of the probability” by simply “proportion of
successes”. These are the proportions that are used in the following designs, which under
the population model converge to the real value of the parameters with an initial value of
1/2 in both cases,
pˆn1 =
Sn,1 + 1/2
Nn,1 + 1
and pˆn2 =
Sn,2 + 1/2
Nn,2 + 1
. (3.8)
Using the relations defined in (3.6) and (3.7), the estimators can be denoted in terms
of Sn and ∆n
pˆn,1 =
n∑
i=1
ai + Sn + 1
n+ ∆n + 2
and pˆn,2 =
n∑
i=1
ai − Sn + 1
n−∆n − 2 . (3.9)
The DBCD designs, see (1.9), is a family of designs based on sequential estimation.
For each n, the allocation rule is
P (δ˜n+1 = 1|Fn) = gα
(
Nn,1
n
, ρˆn
)
, (3.10)
where pˆ0,i = 1/2, with i = 1, 2 and P (δ1 = 1) = 1/2. The proposed probability function
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is
gα(x, y) =

1, x = 0,
0, x = 1,
y(y/x)α
y(y/x)α + (1− y)((1− y)/(1− x))α , (x, y) ∈ (0, 1)× [0, 1],
(3.11)
where the parameter x is referred to the proportion of treatment 1 allocations Nn,1/n and
the parameter y to ρˆn = ρ(pˆn,1, pˆn,2).
The Efficient randomized-adaptive designs (ERADE), see (1.10), have the following
allocation rule,
P (δn+1 = 1|Fn) =

αρˆn, if
Nn,1
n > ρˆn;
ρˆn, if
Nn,1
n = ρˆn;
1− α(1− ρˆn), if Nn,1n < ρˆn.
(3.12)
In each step ρˆn = ρ(pˆn,1, pˆn,2) is calculated and it is compared to the actual proportion
od allocations. If some treatment is underallocated, the probability of assigning this
treatment is reduced, a kind of punishment, tuned with a parameter α.
In the last two designs the allocation rule is a function involving an approach of
ρ = ρ(p1, p2) by means of ρˆn = ρ(pˆn,1, pˆn,2) and the current proportion of treatment 1
allocations.
Proposition 3.2.2. The DBCD designs and the ERADE designs are in the < family.
Proof. In both designs the allocation function is terms of ρˆn = ρ(pˆn,1, pˆn,2) and Nn,1/n.
From (3.9) and the comments after it, we know that ρˆn can be written depending on Sn
and ∆n. Besides this, Nn,1 = n+∆n2 , so, only by function composition, the desired hn(s, l)
is obtained.
Remark 3.2.1. The previous proof is generic, it is valid for any target allocation and
any value of the parameters of the design. It should be noted that it is not difficult to
derive the expression of the hn(s, l) function in any case, but it is complicated and non
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informative. For instante, for DBCD design with the most usual target allocation, RSIHR
allocation and α = 2, can be written as
hn+1(r, l) =
c3n(1− bn)2
c3n(1− bn)2 + (1− cn)3b2n
,
with bn =
n+ l
2n
and cn =
√
(
∑n
i=1 ai) + r + 1√
(
∑n
i=1 ai) + r + 1 +
√
n+l+1
n−l+3
√
(
∑n
i=1 ai)− r + 1
.
Another outstanding design in the < family is the play-the-winner rule, see section
1.1.3. In resume, when a patient arrives to a ball is extracted, the corresponding treatment
is applied and the ball is returned with one ball of the same treatment in case of success
and with one ball of the other treatment in case of failure.
Proposition 3.2.3. The play-the-winner rule is in the < family with
hn+1(r, l) =
2w + n− l + 2r
2(2w + n)
.
Proof. The probability of treatment 1 allocation in the n+1-th step is, as derived in (1.5),
P (δ˜n+1 = 1|Fn) = w + Sn,1 + (Nn,2 − Sn,2)2w + n . (3.13)
Using the relations in (3.6) and (3.7), the result follows.
3.3 Simulation study
In the previous sections an algorithm to compute the exact distribution of the test statistic
under RBI and hence the p-value was presented. Another common technique to compute
the p-value is a Monte Carlo method. The main idea consists in fixing the size of the
Monte Carlo estimator, Kc, and run the trial Kc times. In each run the test statistic
is computed and compared with the observed value, already fixed. The proportion of
times that the value of the statistic is greater than the observed one is the estimator of
the p-value. One important concern about Monte Carlo method is the accuracy of the
estimation. So, a comparative study is done between the exact p-value computed using the
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algorithm presented in the previous section and Monte Carlo simulations of the p-values
with two different values of Kc.
In Table 3.1 the results for two Monte Carlo simulations of p-values for different designs
and the computation of the exact p-values are shown. The test statistic is the difference
between successes in both treatments, Sn =
∑
aiδ˜i = Sn,1 − Sn,2. The total number of
patients is 50. Kc = 2500 and Kc = 15000 are Monte Carlo sample sizes, suggested in
[57] as values that guarantee good levels of accuracy in the estimation. 1000 Monte Carlo
runs are done, showing the mean (sd) of the 1000 runs. The null hypothesis is accepted
if |S50| ≥ 13. In the exact computation, the exact distribution of the test statistic is
computed, showing the corresponding probability tail.
Table 3.1: Monte Carlo estimation of p-value, mean (sd), and exact p-value. Test statistic
Sn
Kc = 2500 Kc = 15000 Exact
CR 0.0145 (0.0024) 0.0146 (0.0010) 0.0146
Efron 0.0013 (0.0007) 0.0013 (0.0003) 0.0013
Klein 0.0385 (0.0039) 0.0385 (0.0016) 0.0385
DBCD α = 0 0.0791 (0.0055) 0.0791 (0.0022) 0.0793
DBCD α = 2 0.0369 (0.0038) 0.0368 (0.0016) 0.0369
ERADE α = 0.5 0.0318 (0.0035) 0.0317 (0.0014) 0.0317
ERADE α = 0.7 0.0340 (0.0037) 0.0340 (0.0015) 0.0341
PTW 0.1326 (0.0110) 0.1327 (0.0027) 0.1326
If we consider the test statistic Tn = Sn,1/Nn,1 − Sn,2/Nn,2, a similar computational
study is done in Table 3.2. The set of responses is fixed and common for all the designs,
and the observed experimental value of the test statistic is also common and fixed in
T = 0.3, i.e. a difference of 0.3 between the percentage of successes in both treatments.
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Table 3.2: Monte Carlo estimation of p-value, mean (sd), and exact value. Test statistic
Tn
Kc = 2500 Kc = 15000 Exact
CR 0.0340 (0.0034) 0.0341 (0.0015) 0.0341
Efron 0.0370 (0.0038) 0.0372 (0.0015) 0.0372
Klein 0.0287 (0.0034) 0.0286 (0.0014) 0.0286
DBCD α = 0 0.0445 (0.0041) 0.0444 (0.0016) 0.0445
DBCD α = 2 0.0383 (0.0040) 0.0383 (0.0016) 0.0382
ERADE α = 0.5 0.0345 (0.0037) 0.0344 (0.0015) 0.0344
ERADE α = 0.7 0.0384 (0.0039) 0.0383 (0.0016) 0.0384
PTW 0.0390 (0.0039) 0.0391 (0.0016) 0.0392
Observing Table 3.1 and Table 3.2, the first conclusion is that the mean estimations are
almost equal to the exact ones in all the designs for both statistics. About the precision of
the statistic, for the Sn statistic a dependence on the particular design is observed. Designs
with large variability in the proportion of allocations are expected to have larger variability
in the statistic. For instance, the case with higher variance in the Monte Carlo statistic is
the PTW design, for which is well-known its high variability. Another remarkable issue is
the uniformity of all the standard deviations in the Tn statistic.
In Table 3.3 a population model is assumed. Now, following [11], we have that under
adaptive designs such that Nn,1 →∞ and Nn,2 →∞ as n→∞, the classical central limit
theorem holds,
H(n, p1, p2) =
pˆn,1 − pˆn,2 − (p1 − p2)√
p1q1
Nn,1
+
p2q2
Nn,2
→ N(0, 1). (3.14)
Then, for each pair of values of p1 and p2 and each allocation rule, m = 1000 executions
of the corresponding clinical trial are made. Table 3.3 computes for several sample sizes
n, n = 30, 50, 100, 200, 500, the proportion of times that H(n, p1, p2) > 1.96. That is, as
we are in the setting of a population model, for a significance level of 0.05, the power of
the Wald test is estimated.
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As expected, for small values of n, n ≤ 50, and small differences between p1 and p2,
the power of the test is smaller than 0.5.
In Table 3.4 the same study is made but a population model is not assumed and now
RBI is used with the Sn statistic. This is not an estimation of the power value, because
this concept does not make sense in this setting, but it is the logical value to be obtained
for comparative studies with power values, see [29], section 13.7, and [56]. The main idea
is that for a randomization model does not exist an alternative hypothesis from which
the data could be generated in order to do the simulation, as under a population model.
So, the data, in our case the responses of the patients, are simulated using a parametric
model, choosing two different success probabilities, and then the power is estimated as
usual. Comparing the different designs, can be noted that the urn models have worse
level of power in very small values of n. We observe that for small values of n and small
differences of the success probabilities, power values are greater than in Table 3.3, except
for the DCBD2 design.
Table 3.5 is as Table 3.4 but the test statistic Tn is chosen instead of Sn. Observe that
both tables provide similar results except in the case p1 = p2 where the significance level
is correctly reached for all the designs even for small values of n. This is quite remarkable
because mitigates the conservativeness of the Sn statistic. We also observe that it takes
the increment of the power for small values of n which was observed in Table 3.4 but for
large values of n the behavior is as its population statistical test counterpart, which is
used in Table 3.3.
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Table 3.3: Proportion of rejections with the Wald test: asymptotic estimations
Sample size
p1, p2 D 10 30 50 100
0.9, 0.3
CR 0.503 0.977 0.998 1.000
Efron 0.603 0.979 0.999 1.000
PTW 0.393 0.904 0.987 1.000
Klein 0.470 0.956 1.000 1.000
DBCD2 0.588 0.978 0.999 1.000
ERADE7 0.494 0.971 0.999 1.000
0.9, 0.5
CR 0.170 0.710 0.925 0.995
Efron 0.150 0.742 0.932 0.997
PTW 0.137 0.602 0.830 0.978
Klein 0.159 0.689 0.881 0.992
DBCD2 0.157 0.715 0.925 0.997
ERADE7 0.149 0.719 0.892 0.995
0.9, 0.7
CR 0.076 0.252 0.421 0.701
Efron 0.074 0.232 0.412 0.730
PTW 0.048 0.228 0.394 0.634
Klein 0.071 0.251 0.410 0.689
DBCD2 0.083 0.248 0.418 0.705
ERADE7 0.067 0.246 0.416 0.698
0.7, 0.3
CR 0.124 0.587 0.823 0.978
Efron 0.158 0.631 0.865 0.988
PTW 0.098 0.582 0.842 0.992
Klein 0.119 0.614 0.838 0.989
DBCD2 0.182 0.626 0.855 0.993
ERADE7 0.128 0.618 0.832 0.982
0.7, 0.5
CR 0.046 0.179 0.312 0.525
Efron 0.038 0.130 0.294 0.527
PTW 0.035 0.174 0.261 0.514
Klein 0.046 0.174 0.296 0.520
DBCD2 0.046 0.190 0.312 0.532
ERADE7 0.051 0.169 0.273 0.513
0.7, 0.7
CR 0.019 0.042 0.040 0.041
Efron 0.013 0.040 0.046 0.046
PTW 0.015 0.043 0.052 0.043
Klein 0.017 0.046 0.050 0.046
DBCD2 0.012 0.037 0.043 0.039
ERADE7 0.017 0.043 0.036 0.040
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Table 3.4: Proportion of rejections with the randomization test (exact p-values) with test
statistic Sn.
Sample size
p1, p2 D 10 30 50 100
0.9, 0.3
CR 0.382 0.705 0.861 0.994
Efron 0.656 0.963 0.998 1.000
PTW 0.028 0.611 0.870 0.999
Klein 0.169 0.843 0.984 1.000
DBCD2 0.315 0.659 0.904 0.999
ERADE7 0.606 0.952 0.997 1.000
0.9, 0.5
CR 0.247 0.330 0.475 0.713
Efron 0.399 0.736 0.912 0.997
PTW 0.025 0.267 0.483 0.808
Klein 0.072 0.441 0.756 0.981
DBCD2 0.170 0.327 0.529 0.880
ERADE7 0.314 0.689 0.890 0.994
0.9, 0.7
CR 0.136 0.151 0.175 0.241
Efron 0.230 0.308 0.452 0.739
PTW 0.025 0.085 0.132 0.243
Klein 0.023 0.122 0.271 0.605
DBCD2 0.137 0.097 0.141 0.293
ERADE7 0.182 0.308 0.460 0.728
0.7, 0.3
CR 0.324 0.468 0.602 0.854
Efron 0.447 0.722 0.879 0.989
PTW 0.005 0.307 0.575 0.916
Klein 0.069 0.419 0.732 0.969
DBCD2 0.285 0.284 0.488 0.868
ERADE7 0.400 0.630 0.815 0.981
0.7, 0.5
CR 0.184 0.159 0.182 0.277
Efron 0.224 0.271 0.355 0.576
PTW 0.006 0.086 0.146 0.302
Klein 0.018 0.121 0.220 0.458
DBCD2 0.115 0.072 0.096 0.204
ERADE7 0.199 0.242 0.326 0.552
0.7, 0.7
CR 0.121 0.072 0.063 0.064
Efron 0.200 0.112 0.120 0.081
PTW 0.010 0.036 0.034 0.044
Klein 0.007 0.017 0.020 0.015
DBCD2 0.099 0.016 0.010 0.009
ERADE7 0.134 0.087 0.072 0.071
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Table 3.5: Proportion of rejections with the randomization test (Monte Carlo estimations
of the p-values) and test statistic T .
Sample size
p1, p2 D 10 30 50 100
0.9, 0.3
CR 0.552 0.960 0.999 1.000
Efron 0.657 0.969 1.000 1.000
PTW 0.334 0.919 0.996 1.000
Klein 0.430 0.948 0.995 1.000
DBCD2 0.423 0.955 0.998 1.000
ERADE7 0.349 0.938 0.996 1.000
0.9, 0.5
CR 0.325 0.699 0.895 0.998
Efron 0.385 0.765 0.927 0.999
PTW 0.164 0.666 0.870 0.991
Klein 0.196 0.676 0.863 0.994
DBCD2 0.263 0.691 0.896 0.996
ERADE7 0.152 0.646 0.865 0.995
0.9, 0.7
CR 0.157 0.278 0.439 0.754
Efron 0.202 0.347 0.487 0.750
PTW 0.066 0.216 0.377 0.670
Klein 0.053 0.217 0.395 0.696
DBCD2 0.160 0.262 0.440 0.717
ERADE7 0.060 0.229 0.390 0.717
0.7, 0.3
CR 0.239 0.614 0.822 0.981
Efron 0.350 0.677 0.860 0.986
PTW 0.156 0.539 0.775 0.986
Klein 0.163 0.567 0.804 0.978
DBCD2 0.298 0.559 0.802 0.982
ERADE7 0.146 0.544 0.808 0.980
0.7, 0.5
CR 0.136 0.227 0.328 0.544
Efron 0.168 0.226 0.328 0.564
PTW 0.075 0.171 0.273 0.493
Klein 0.063 0.181 0.266 0.520
DBCD2 0.118 0.182 0.263 0.494
ERADE7 0.043 0.157 0.265 0.518
0.7, 0.7
CR 0.062 0.060 0.043 0.051
Efron 0.092 0.073 0.069 0.073
PTW 0.030 0.048 0.038 0.046
Klein 0.028 0.042 0.042 0.040
DBCD2 0.084 0.053 0.045 0.046
ERADE7 0.030 0.026 0.044 0.046
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3.4 Randomization based inference for the DTL design
Although the < family includes most of the response-adaptive designs considered in the
literature, the designs based on immigrated urn models, see [79], do not belong to it. The
DTL design, see (1.6), is one of them. When a treatment ball is extracted, the patient
is allocated to this treatment, as usual. But when an immigration ball is extracted, no
treatment is applied and a change in the urn composition is done, so there is a break up
between ball extractions and treatment allocations. Due to this break up, these type of
designs cannot be included in the < family. The probability of allocation is no longer a
function of Sn and ∆n, because the number of immigration balls drawn until the present
allocation is also a required information to determine the probability distribution of the
allocation rule. Furthermore, the number of consecutive immigration ball extractions can
be any non-negative number, so the probability of treatment 1 allocation only can be
expressed by an infinite sum, not in a closed function form.
In [79], theoretical properties for a wide range of urn models have been presented
under an unified approach called immigrated urn models. In addition to this, applications
of immigrated urn models in clinical trials are also studied under the assumption of a
population model. We assume the randomization model, with a fixed set of responses
An = {Y1 = a1, Y2 = a2, . . . , Yn = an}, so the results in [79] are not applicable in our case.
For this reason, a particular study of RBI for these designs is of interest. We will focus
on the DTL design, which behavior was presented in section 1.1.3. The number of type
1 balls in the urn after the mth replacement and the total number of balls are denoted,
respectively, by Wm,1 and Tm. So W0,1 = w and T0 = 2w + 1. Observe that, due to the
presence of a type 0 ball, the number of replacements, m, is not necessarily equal to the
number of patients, n, that have participated in the experiment, being n ≤ m.
The theoretical treatment of the model is complicated, due to the duality between urn
extractions and treatment allocations. In order to express the model mathematically we
need to introduce some notation. For each extraction m, m = 1, 2, · · · , ϕm is a random
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variable which equals 1 when a ball of type 1 is drawn, -1 when the ball is of type 2 and
0 when the ball is of type 0. Let ∆m =
∑m
i=1 ϕi be the unbalance between the number
of patients allocated to each treatment after the m-th replacement. If Nm,1 and Nm,2
are, as usual, the number of patients allocated to treatment 1 and treatment 2 up to and
including the mth replacement, then ∆m =
∑m
i=1 ϕi = Nm,1−Nm,2. If we denote as Nm,0
the number of type 0 balls drawn up to the mth replacement, we can express this quantity
as Nm,0 = m−Nm,1 −Nm,2.
Finally, let Fm = σ(Gm,Zm) denote the natural sigma algebra generated by all the
previous allocations and responses up to the m-th replacement. Then,
P (ϕm+1 = 1|Fm) = Wm,1
Tm
, P (ϕm+1 = 0|Fm) = 1
Tm
. (3.15)
As the number of extractions does not correspond with the number of treatment allo-
cations, additional notation should be included. Let {τm}m≥0 be a sequence of stopping
times which represents, for each m, the number of patients allocated up to the mth re-
placement. Observe that taking τ0 = 0 then, for m ≥ 1, τm =
∑m
i=1 ϕ
2
i , because ϕ
2
i is
equal to 1 if any treatment has been applied and equal to 0 if an immigration ball has
been extracted and then, there has not been any treatment allocation. It also holds that
τm =
∑m
i=1 ϕ
2
i = Nm,1 +Nm,2. Observe that using the expressions from above, Nm,1 and
Nm,2 can be expressed as Nm,1 =
∑m
i=1(ϕi + ϕ
2
i )/2 and Nm,2 =
∑m
i=1(ϕ
2
i − ϕi)/2.
Let Sn be the difference between the number of successes in the two treatments once n
patients have responded under the DTL rule. Observe that a type 0 ball can be extracted
in each step and this implies that the number of extractions of type 0 balls between
two allocations is an unbounded random variable. It will be helpful to define S∗m, the
difference between the number of successes up to and including the mth extraction, so
consider S∗m =
∑m
i=1 aτiϕi.
As in the previous sections, Sn is chosen as the randomization test statistic for studying
the equality of treatments. We are interested in computing the exact distribution of Sn.
Observe that the event {Sn = s} can be expressed as the a union of disjoint events indexed
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by m ≥ n, and then,
P (Sn = s) =
∞∑
m=n
P (S∗m = s, τm = n, ϕm 6= 0). (3.16)
Note that this decomposition is significantly different from the decomposition in (3.2).
Now, the probability is an infinite sum, because of the possibility of extracting any number
of immigrations balls without applying any treatment allocation. The following technical
proposition will be crucial for computing the exact p-values of the randomization test
based on the Sn statistic for the DTL design. The algorithm is inspired by Proposition
3.1.1, adapted to the new urn with three different type of balls.
Proposition 3.4.1. Assume that the DTL design is applied as allocation rule. Consider
for each replacement m ≥ 1 the random variables ϕm, ∆m and τm defined as before. Then,
P (S∗m = s, τm = n, ϕm 6= 0), −n ≤ s ≤ n, (3.17)
can be calculated with a recursion formula with initial values
P (S∗1 = 0, τ1 = 0, ∆1 = 0) =
1
2w + 1
,
P (S∗1 = 0, τ1 = 1, ∆1 = −1) = P (S∗1 = 0, τ1 = 1, ∆1 = 1) = (1− a1)
w
2w + 1
,
P (S∗1 = −1, τ1 = 1, ∆1 = −1) = P (S∗1 = 1, τ1 = 1, ∆1 = 1) = a1
w
2w + 1
.
Proof. The probability in (3.17) can be decomposed as
P (S∗m = s, τm = n, ϕm = r) =
n∑
i=−n
P (S∗m = s, τm = n, ∆m = i, ϕm = r).
Observe that for each extraction m ≥ 1 we have
P (S∗m = s, τm = k, ∆m = i, ϕm = r) =
P (ϕm = r|S∗m−1 = s− akr, τm−1 = k − r2, ∆m−1 = i− r)
×P (S∗m−1 = s− akr, τm−1 = k − r2, ∆m−1 = i− r). (3.18)
On the other hand, in order to have a solvable recurrence, we need to express the number
of total balls and type 1 balls as a function of the elements in the conditional part of
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(3.18). Considering that after each immigration ball two other balls are added to the urn
and after a success in a treatment one ball is dropped, we can express the total number
of balls as
Tm = 2w + 1 + 2Nm,0 −
τm − τm∑
j=1
aj
 = 2w + 1 + 2m− 3τm + τm∑
j=1
aj .
A similar calculation for the number of type 1 balls leads to
Wm,1 =
Tm − 1 + S∗m −∆m
2
;
so, for r = 1 and r = 0 we can explicitly express
P (ϕm = 1|S∗m−1 = l1, τm−1 = l2, ∆m−1 = l3) =
2w+1+2m−3l2+
l2∑
j=1
aj − 1 + l1 − l3
2
2w+1+2m−3l2+
l2∑
j=1
aj

,
P (ϕm = 0|S∗m−1 = l1, τm−1 = l2, ∆m−1 = l3) = 1
2w+1+2m−3l2+
l2∑
j=1
aj
.
A closed expression for all the values of r can be obtained,
P (ϕm = r|S∗m−1 = l1, τm−1 = l2, ∆m−1 = l3) =
r2(l1 − l3)) + r(Tm−1 − 1) + 2
2Tm−1
. (3.19)
Finally, a recursion is obtained by plugging (3.19) into (3.18).
When randomization is made with the DTL design, Proposition 3.4.1 and equation
(3.16) allow us to obtain exact calculations of p-values when RBI is used with the test
statistic Sn.
Remark 3.4.1. As can be seen in (3.16), the probability P (Sn = s) is an infinite sume of
elements. With the recursive algorithm each summand can be computed, but to compute
the whole summation an approximation level must be fixed. This level is going to be an
error in the exact calculation, however, this error could be as small as we want.
Remark 3.4.2. As happened in Remark 3.1.1 with the < family of designs, other test
statistics distributions can be computed exactly when the DTL rule is applied. A good
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estimator of p1 − p2 is Sn,1/Nn,1 − Sn,2/Nn,2. Let Tn be the difference between success
proportions for each treatment when the n patients have been allocated with the DTL
rule. Reasoning as in (3.16), it follows that if T ∗m is the difference of success proportions
up to and including the mth ball extraction, then,
P (Tn = t) =
∞∑
m=n
n∑
k=0
P (T ∗m = t, ∆m = 2k − n, τm = n, ϕm 6= 0)
=
∞∑
m=n
n∑
k=0
P (S∗m = r(k), ∆m = 2k − n, τm = n, ϕm 6= 0)
where r(k) = (2t ∗ k ∗ (n − k) − (n − 2k)∑ni=1 ai)/n. Now, using Proposition 3.4.1, any
p-value for the distribution of Tn can be obtained.
In Table 3.6 we replicate the procedure of Table 3.1 for the DTL design, using the
recurrence algorithm for this design. Comparing the computed p-values with the results
for the Klein urn design, there are significant differences, so even both designs show a
similar asymptotic behavior, this result suggests some differences between the behavior of
both designs in small or moderate sample sizes.
Table 3.6: Monte Carlo estimation of p-value, mean (sd), and exact p-value for the DTL
design. 50 patients. Test statistic Sn
Kc = 2500 Kc = 15000 Exact
CR 0.0145 (0.0024) 0.0146 (0.0010) 0.0146
Klein 0.0385 (0.0039) 0.0385 (0.0016) 0.0385
DTL 0.0596 (0.0048) 0.0595 (0.0020) 0.0595
Chapter 4
Asymptotic randomization based
inference for the Klein urn design
Randomization based inference has been shown as an adequate alternative to population
based inference when the assumption of the population model is not appropriate. However,
some of the principal drawbacks of this kind of inference is due to the enumeration and
the computation of the probability of all the possible data permutations. This could be
computationally unfeasible. In order to avoid this problem, one option is the development
of algorithms to shorten the calculations, as the one presented in Chapter 3. Other
alternative is to obtain the asymptotic distribution of the test statistic. The computation
of the asymptotic distribution of the randomization test under the Klein urn design has
two main problems. One the one hand, due to the particular dependence structure of the
allocations, standard central limit theorems are not valid and a specific calculation needs to
be done. On the other hand, when the randomization model is assumed, the responses are
considered fixed, so the dynamics of the design changes and the stochastic properties have
to be studied under the new paradigm. In section 1 the Klein urn under the randomization
model is presented and studied, partially replicating the results of Chapter 2. In section 2,
the asymptotic distribution of the randomization test statistic is computed under certain
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conditions, also analyzing the adequacy of these conditions.
The contents of this chapter have been collected in [25].
4.1 Klein urn design under randomization model
Under a population model, the response of the nth patient is Yn = δnZn,1 + (1− δn)Zn,2,
where, for i = 1, 2, Zn,i are independent and identically distributed random variables
with Bernoulli distribution of parameter pi. The fact of having these random responses
has a strong influence in the behavior of the urn and therefore in the properties of the
design in general. For example, the evolution of the number of balls of type 1 in the
urn, {Wn,1}, n ∈ N, the process which mainly determines the behavior of the design, is a
homogeneous Markov chain with states E = {0, 1, . . . , 2w} and transition probabilities
pi,j =

q2(1− i2w ), j = i+ 1,
p1
i
2w + p2(1− i2w ), j = i,
q1
i
2w , j = i− 1,
0, otherwise.
i, j = 0, . . . , 2w.
When the response of a patient is a success, the urn composition remains unchanged,
when it is a failure, we do not return the ball and a ball of the other type is added.
This dual behavior is due to the random binary responses, and the Markov chain Wn,1
has a homogeneous representation. Under the randomization model, the responses are
deterministic so both behaviors must be distinguished. In the sequel, the set of responses
An = {Y1 = a1, Y2 = a2, · · · , Yn = an} is considered fixed and all the random variables
are conditioned to this set of responses. Analyzing the new urn model, when the (de-
terministic) response after any treatment application is a success, we do not change the
composition of the urn. In case of a (deterministic) failure, the number of balls of the
applied treatment decreases one unit and the number of balls of the other type increases
one unit. The behavior of the urn in case of failure is the same as the Ehrenfest urn
model. Under this new paradigm, the number of type 1 balls in the urn is no longer a
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homogeneous Markov chain. The markovian property is not lost, but due to the duality
in the behavior of {Wn,1}, the chain is now a non-homogeneous Markov chain. Besides
this, the expectation and the variance of the variables of the process must be recalculated
under the new paradigm.
Proposition 4.1.1. Assume that the Klein design has been applied to a set of n patients
and the responses are An. The initial number of balls of type 1 is a random variable W0,1
such that E[W0,1] = w. Then,
a) The process {Wn,1} is a non-homogeneous Markov Chain with state space E =
{0, 1, . . . , 2w} such that, for each n, the transition probability matrix is Pn = anI + (1−
an)P . Where I is the identity matrix of order 2w + 1 and P is the transition matrix of
the classical Ehrenfest Urn model
P (i, j) =

1− i
2w
, j = i+ 1
i
2w
, j = i− 1
0, otherwise.
i, j ∈ E.
b) Let fn =
∑n
i=1(1− ai) be the number of failures up to n, then, for each n,
E[Wn,1] = w and V ar[Wn,1] =
w
2
(
1−
(
1− 2
w
)fn (
1− 2
w
V ar[W0,1]
))
.
Proof. For each n we have
Wn,1 = Wn−1,1 − (1− an)δ˜n (4.1)
To prove a), observe that when the response of the i-th patient is successful, the chain
does not change, Wn,1 = Wn−1,1. Otherwise, it jumps to the neighbor states as in the
classical Ehrenfest process. So, the transition matrix is the combination of both transitions
matrices, depending on the deterministic responses.
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Taking expectations in (4.1), we have that
E[Wn,1 − w] = E[Wn−1,1 − w]− (1− an)E
[
E[δ˜n|Wn−1,1]
]
=
(
1− 1− an
w
)
E[Wn−1,1 − w]
=
n∏
i=1
(
1− 1− ai
w
)
E[W0,1 − w] ,
as E[W0,1] = w, then E[Wn,1] = w. Also from (4.1) we have
E
[
(Wn,1 − w)2
]
= E
[
(Wn−1,1 − w)2
]
+ (1− an)− 2(1− an)E
[
(Wn−1,1 − w) δ˜n
]
=
(
1− 21− an
w
)
E[(Wn−1,1 − w)2] + (1− an) ,
so that, if an = 1 we have that V ar[Wn,1] = V ar[Wn−1,1], otherwise,
V ar[Wn,1] =
(
1− 2
w
)
V ar [Wn−1,1] + 1
=
fn−1∑
i=0
(
1− 2
w
)i
+
(
1− 2
w
)fn
V ar[W0,1] .
Then, V ar[Wn,1] =
w
2
(
1−
(
1− 2
w
)fn (
1− 2
w
V ar[W0,1]
))
as stated in b).
Remark 4.1.1. Note how in the number of type 1 balls process, {Wn,1}, the random vari-
ables are centered for each n considering the urn state space [0, 2w], when the responses
are fixed. It can be understood if we think that the number of balls in the urn is skewed
when a treatment performs better than another treatment, i.e. when the success probabil-
ity of one treatment is greater than the other one, if we were under the population model.
In our case, under the randomization model, the treatments are considered equivalent and
the responses are fixed, so the concept of probability of success disappears, but we can
think that the urn performs as the success probabilities were equal. For this reason, the
expected number of balls is w for each n.
Remark 4.1.2. Observing the expression of the variance of Wn,1 in Proposition 4.1.1,
some conclusion can be obtained. If the number of failures converges to infinity, fn →∞,
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then V ar[Wn,1]→ w2 and this convergence is monotonous, since
(
1− 2
w
)fn
is monotonous.
Besides this,
if V ar[W0,1] > w2 then, {V ar[Wn,1]} is strictly decreasing,
if V ar[W0,1] = w2 then, {V ar[Wn,1]} is equal to w2 for each n,
if V ar[W0,1] < w2 then, {V ar[Wn,1]} is strictly increasing.
In Chapter 2, during the study of the properties of the Klein urn design under a
population model, we have emphasized the importance of the fact that the number of
balls of type 1 is a homogeneous Markov chain and the importance of this property in the
study of almost all the processes of the design. Under the randomization model, {Wn,1}
is non-homogeneous Markov chain, so an important change in the treatment’s allocation
process {δn} is expected. In the next proposition new properties of the process {δn} are
studied.
Proposition 4.1.2. Assume that the Klein design has been applied to a set of n patients
and the responses are An. Then,
a) For each n
E[δn] =
1
2
and V ar[δn] =
1
4
and
E[δ˜n] = 0 and V ar[δ˜n] = 1
b) The components of the covariance matrix of the vector δn = {δ1, ..., δn}, are
Σδn(i, j) =

V ar[δi], i = j
1
4w2
V ar[Wi−1,1]− (1− ai)4w , j = i+ 1;(
1− 1
w
)fj−fi
Cov(δi, δi+1), j > i+ 1
c) The covariance matrix of the sequence of martingale differences {δi − E[δi|Fi−1]},
i = 1, . . . , n, is a diagonal matrix with
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Σδn−E[δn|Fn−1](i, i) =
1
4
(
1− 1
w2
V ar[Wi−1,1]
)
.
Proof. From Proposition 4.1.2 part b), E[Wn−1,1] = w, so,
E[δn] = E[Wn−1,1/(2w)] =
1
2
.
For the variance,
V ar[δn] = E
[(
δn − 12
)2]
=
1
4
,
and a) follows.
For b) observe that
Cov(δi, δi+1) = E[δiE[δi+1|Wi,1]− E[δi]E[δi+1]
=
1
2w
E[δiWi,1]− 14
=
1
2w
E[δi(Wi−1,1 − (1− ai)(2δi − 1))]− 14
=
1
2w
(E[δiWi−1,1]− (1− ai)E[δi])− 14
=
1
4w2
(E[(Wi−1,1)2]− (1− ai)w)− 14
=
1
4w2
V ar[Wi−1,1]− 1− ai4w ,
and also, for j > i+ 1,
Cov(δi, δj) =
1
2w
E[δiWj−1,1]− 14
=
1
2w
E [δi(Wj−2,1 − (1− aj−1)(2δj−1 − 1))]− 14
=
1
2w
(
E[δiWj−2,1]− (1− aj−1)
(
2E[δiδj−1]− 12
))
− 1
4
= E[δiδj−1]− 1− aj−1
w
(
E[δiδj−1]− 14
)
− 1
4
=
(
1− 1− aj−1
w
)
Cov(δi, δj−1) ,
and c) follows.
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Observe that for any j > i, with i, j = 1, . . . , n we have that
Cov(δi − E[δi|Fi−1], δj − E[δj |Fj−1]) = Cov(δi, δj)− Cov(δi, E[δj |Fj−1)
− Cov(E[δi|Fi−1], δj)
+ Cov(E[δi|Fi−1], E[δj |Fj−1]) .
From Lemma 2.2.1, and noting that δi and E[δi|Fi−1] are Fj−1-measurable,
Cov(δi, δj) = Cov(δi, E[δj |Fj−1) and Cov(E[δi|Fi−1], δj) = Cov(E[δi|Fi−1], E[δj |Fj−1]),
then, the set of variables {δi − E[δi|Wi−1]}i=1,...,n are incorrelated. Besides this,
V ar(δi − E[δi|Wi−1,1]) = E[δi]− E
[
(Wi−1,1)2
4w2
]
=
1
2
− V ar[Wi−1,1] + w
2
4w2
=
1
4
− V ar[Wi−1,1]
4w2
,
so, the proposition is proved.
Remark 4.1.3. Note that δ˜n = 2δn − 1 and (δ˜n − E[δ˜n|Fn−1]) = 2 (δn − E[δn|Fn−1]),
so, the covariance matrices follow the same relation, Σδn=4Σδ˜n and Σδn−E[δn|Fn−1]=
4Σδ˜n−E[δ˜n|Fn−1].
In order to continue the study of the properties of the design, the presence of the
non-homogeneous Markov chain {Wn,1} makes it more difficult, specially in asymptotic
theory. The principal concern about the asymptotic behavior of a Markov chain is the
existence of an invariant or long run distribution. This property is called ergodicity, and it
can be thought as a kind of stabilization of the chain. A chaotic behavior of the transition
matrix would make the asymptotic study unfeasible. If some kind of stabilization could
be guaranteed, the asymptotic study would become reasonable. In [38], Chapter V, a
study of different types of ergodic properties for non-homogeneous Markov chains is done.
Almost all the results are based on the Dobrushin’s ergodic coefficient.
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In the Klein urn design under the randomization model, as it has been seen in Propo-
sition 4.1.1, the process {Wn,1} gets stuck or moves randomly as in the classical Ehrenfest
model, so it is a deterministic combination of two different and well known chains. Using
this property, the ergodicity of {Wn,1} is proven in the next lemma.
Lemma 4.1.1. Assume the conditions of Proposition 4.1.2 and that fn =
∑
(1− ai) ↑ ∞
when n→∞. Then, the non-homogeneous Markov-Chain {Wn,1} is strongly ergodic.
Proof. From Proposition 4.1.2 we have that {Wn,1} is a non-homogeneous Markov Chain
with transition probability Pn = anI+(1−an)P . In case of a success the transition matrix
is the identity and in case of failure it is the Ehrenfest urn model transition matrix. The
n-step transition matrix has an easy form, P (k,k+n) =
∏k+n
i=k Pi = P
fk+n−fk , depending
only in the number of failures. As n→∞, fn →∞ and then
P (k,k+n) =
k+n∏
i=k
Pi = P fk+n−fk → 1tpi .
where 1t is a column vector of ones and pi is the stationary distribution of the classical
Ehrenfest urn model, which is a binomial distribution with parameters 2w and 1/2, see, for
instance, Proposition 2.1.2. The n-step transition matrix converges to a constant matrix
when n goes to infinity, so then, from Theorem V.4.1 in [38], the result follows.
Strong laws and central limit theorems for non-homogeneous Markov Chains remain
still as a research topic in Probability Theory. Some advances can be found in the literature
to obtain a strong law of large numbers for {Wn,1}. Here a modification of a result in [44]
is presented.
Proposition 4.1.3. Assume the conditions of Proposition 4.1.2. Let {gn}, n ≥ 0, be a
sequence of real functions defined on the state space E. If |gn(Wn,1)| ≤ M , n ≥ 0 and
fn ↑ ∞ when n→∞, then
lim
n→∞
1
n
n∑
i=1
(gi(Wi,1)− Egi(Wi,1)) = 0.
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Proof. We are going to apply Corollary 1 in [44]. The δ coefficient of a stochastic matrix
P = (p(i, j)) is defined as
δ(P ) =
1
2
sup
i,k
∑
j
|p(i, k)− p(k, j)|
In Lemma 4.1.1 we prove the strong ergodicity of the Markov chain {Wn,1}, so, the δ
coefficient of the Corollary tends to 0 as is demanded (actually, this coefficient is 0 in
all steps). Assuming |gn(Wn,1)| ≤ M , all the conditions are fulfilled and the strong law
follows.
This proposition is very useful to prove some limit theorems for some moments of
{Wn,1}.
Corollary 4.1.1. Consider the non-homogeneous Markov Chain {Wn,1} and assume that
fn ↑ ∞ when n→∞, then
n∑
i=1
Wi,1
n
→ w, a.s. when n→∞ (4.2)
n∑
i=1
(Wi,1)2
n
→ w2 + w
2
, a.s. when n→∞ . (4.3)
4.2 RBI for large samples
As stated in Chapter 1 and Chapter 3, when a population model is not appropriate to
make inference, RBI appears as a plausible alternative. We are going to consider the test
statistic presented in the previous chapter,
Sn =
n∑
i=1
aiδ˜i, (4.4)
a version of a rank statistic for binary responses, as in [60]. In the Chapter 3, the work
was focused on the exact properties of the statistic, in this chapter, however, the study is
about the asymptotic behavior of the statistic.
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In order to examine asymptotic properties of Sn, a very common modification is done.
By means of a change in the coefficients, Sn is converted into a martingale. This change
gives a stronger stochastic structure to manage, but in return, the coefficients become
more difficult.
Lemma 4.2.1. Assume that the Klein design has been applied to a set of n patients and
the responses are An. Then Sn can be written as follows:
Sn =
n∑
j=1
bjn
(
δ˜j − E[δ˜j |Fj−1]
)
, (4.5)
where {bjn}j=1,...,n is a sequence of coefficients which depend uniquely on An as stated
explicitly in (4.8).
Proof. Observe that as Wj,1 = ω +
j∑
i=1
δ˜i(ai − 1), then
E[δ˜j |Wj−1,1] = Wj−1,12ω −
(
1− Wj−1,1
2ω
)
=
Wj−1,1
ω
− 1
=
1
w
j−1∑
i=1
δ˜i(ai − 1). (4.6)
Hence
n∑
j=1
bjn
(
δ˜j − E[δ˜j |Fj−1]
)
=
=
n∑
j=1
bjnδ˜j +
1
w
n∑
j=1
bjn
j−1∑
k=1
δ˜k(1− ak)
=
n∑
j=1
bjnδ˜j +
1
w
n−1∑
k=1
 n∑
j=k+1
bjn
 δ˜k(1− ak)
= bnnδ˜n +
n−1∑
j=1
bjn + 1− aj
w
n∑
k=j+1
bkn
 δ˜j (4.7)
LetAn andBn be, respectively, the column vectors (a1, a2, . . . , an)t and (b1n, b2n, . . . , bnn)t.
Let Cn be the upper triangular matrix of order n with Cn(i, i) = 1 and Cn(i, j) =
1− ai
w
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for i = 1, . . . , n and j > i . If we equate the coefficients of δ˜i in (4.7) and Sn, we have, for
each value n,
An = CnBn.
We observe that C−1n is, also, an upper triangular matrix of order n with C−1n (i, i) = 1 and
C−1n (i, i+ 1) = −
1− ai
w
for i = 1, . . . , n− 1 and C−1n (i, j) =
(
1− 1− aj−1
w
)
C−1n (i, j − 1)
for j > i+ 1. So that, the coefficients {bnj}, j = 1, . . . , n, depend uniquely on the values
of An because
Bn = C−1n An
for each value n, we have that bnn = an and for i = 1, . . . , n− 1,
bin =

1, if ai = 1
n∑
j=i+1
−1
w
(1− 1
w
)fj−1−fiaj , if ai = 0.
(4.8)
We can use martingale techniques to study the asymptotic distribution of Sn consid-
ering
Mk,n =
k∑
j=1
bjn
(
δ˜j − E[δ˜j |Fj−1]
)
, (4.9)
where, from Lemma 4.2.1, Mn,n = Sn. The set {Mk,n,Fkn = Fk, k = 1, . . . , n ≥ 1} is
a square integrable triangular array of martingales with mean 0. Our target now is to
obtain an appropriate normalizing sequence {kn} such that
Sn√
kn
→ N (0, σ2) . (4.10)
This is not an direct task, because the computation of the variance of Sn in terms of the
coefficients Bn can be complicated, due to the relationship between both set of coefficients.
A manageable expression of the variance of Sn with the Bn coefficients would be desired.
The results in Proposition 4.1.2 about the covariance structure of the {δ˜n} process becomes
very useful.
88
Proposition 4.2.1. Assume that the Klein design has been applied to a set of n patients
and the responses are An. Assume also that sn = n−fn ↑ ∞ as n→∞. For kn =
∑n
j=1 b
2
jn
we have that
V ar
(
Sn√
kn
)
→ 1− 1
2ω
when n→∞.
Proof. From Lemma 4.2.1 and Proposition 4.1.2 c) we have that
V ar[Sn] = BtnΣδ˜n−E[δ˜n|Wn−1]Bn
= Btndiag(d1, . . . , dn)Bn
=
n∑
j=1
djb
2
jn (4.11)
where di = 1− V ar[Wi−1,1]
w2
, i = 1, . . . , n because δ˜n = 2δn − 1.
From the definition of bjn in (4.8), if aj = 1 then b2jn = 1, so if sn =
∑n
j=1 aj grows
to infinite, kn =
∑n
j=1 b
2
jn also does. From Proposition 4.1.2 we know that di → 1 − 12w .
Then, using Toeplitz lemma, we finally have
V ar
[
Sn√
kn
]
=
n∑
j=1
b2jndj
n∑
j=1
b2jn
−→ 1− 1
2ω
.
Remark 4.2.1. It is worth observing that, for each n, V ar[Sn] = AtnΣδ˜nAn, and then,
V ar[Sn] = 4AtnΣδnAn. So, we also have an expression for the variance in terms of the re-
sponses, An, and the covariance matrix Σδn which is already known from Proposition 4.1.2.
Therefore, if Cn is the matrix introduced in Lemma 4.2.1 andGn =
√
(diag(d1, . . . , dn))C−1n ,
then Σδ˜n = G
t
nGn and we have another expression for the variance,
V ar[Sn] = AtnΣδ˜nAn = (GnAn)
t(GnAn) .
The next theorem is a central limit theorem for the test statistic Sn. Due to the
modification of the statistic done in Lemma 4.2.1, we can appeal to Theorem 3.2 and
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Corollary 3.2 in [30]. This theorem is a central limit theorem for martingale triangular
arrays, under some conditions for the martingale difference process. These conditions
require to add an extra condition about the {bjn} coefficients. The effect of this condition
will be discussed later. Lets consider the notation bn = Θ(an), as usual, that there exists
constants k1 and k2 such that, ∀n > n0, k1an ≤ bn ≤ k2an.
Theorem 4.2.1. Assume that as n → ∞, fn ↑ ∞ and sn = n − fn ↑ ∞. Assume also
that
b2jn
n∑
j=1
b2jn
= Θ
(
1
n
)
(4.12)
then
Sn√∑n
j=1 b
2
jn
→ N
(
0,
√
1− 1
2ω
)
. (4.13)
Proof. For each n, we consider [n] = maxk=1,...,n{k : bkn 6= 0}. Since sn → ∞, an = 1
cases appears in infinity times, thus so does bkn = 1 and [n] diverges.
Let Fk = σ(W1,1, . . . ,Wk,1) and Mk,n as in (4.9)
Mk,n =
k∑
j=1
bjn
(
δ˜j − E[δ˜j |Fj−1]
)
.
Is already known that Mn,n = M[n],n = Sn and {Mk,n,Fkn = Fk, k = 1, . . . , [n] ≥ 1} is
a square integrable triangular array of martingales with mean 0.
For each n and i ≤ [n] we have that Mi,n =
∑i
k=1Xkn, where
Xkn =
bkn(δ˜k − E[δ˜k|Fj−1])√∑n
j=1 b
2
jn
.
We appeal now to Theorem 3.2 and Corollary 3.2 in [30] to obtain a central limit
theorem for {Mk,n}. We have to check the following conditions
max
k
|Xk,n| → 0, in probability, (4.14)∑
k
X2k,n → η2, in probability, (4.15)
E
(
max
k
X2k,n
)
is bounded, (4.16)
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where η2 is a positive random variable.
The sequence {δ˜k − E[δ˜i|Wk−1,1]} is bounded and b
2
jn∑n
j=1 b
2
jn
is also bounded, so (4.16)
holds. Using also the bound for {δ˜k − E[δ˜i|Fj−1]} and the condition b
2
jn∑n
j=1 b
2
jn
= Θ
(
1
n
)
,
(4.14) also holds.
To check (4.15), we consider, for each n, the auxiliar random variable X˜k,n =
1√
n
(δ˜k−
E[δ˜k|Fj−1]), for k = 1, . . . , n. Observe that δ˜n = 2δn − 1 and then
n∑
k=1
X˜2k,n =
4
n
n∑
k=1
(
δk − 2Wk−1,12w δk +
(
Wk−1,1
2w
)2)
(4.17)
On the other hand, we have from the Borel-Cantelli lemma for Martingales and Corol-
lary 4.1.1 that
n∑
k=1
δk
n
→ w,
n∑
k=1
δkWk−1,1
n
→ w
2
+ w2and
n∑
k=1
(Wk−1,1)2
n
→ w
2
+ w2 a.s.
Therefore, from (4.17), we conclude that
n∑
k=1
X˜2k,n is convergent.
Observe that from (4.2) and from the definition of [n], for each 1 ≤ k ≤ [n], there
exists n0 ≥ 1 and positive constants K1, K2 > 0 such that for each n ≥ n0 we have that
K1/n ≤ b
2
kn∑n
j=1 b
2
jn
≤ K2/n. From Theorem 12.4 in [42] it follows that the series
n∑
k=1
X˜2k,n
and
n∑
k=1
X2k,n =
[n]∑
k=1
X2k,n converge or diverge together. So that, condition (4.16) holds and,
then, Sn converges to a normal distribution with zero mean and variance η2 which satisfies
η2 = lim
n→∞V ar
 Sn√∑n
j=1 b
2
jn
 .
Now, from Proposition 4.2.1, η2 = 1− 1
2w
and the theorem is proved.
It is not difficult to find out examples where condition (4.2) does not hold. For instance,
assume that the sequence of responses is always successful except for the first patient, that
is, a1 = 0 and ai = 1 for i ≥ 2. Then, for each n, bn1 = −(n − 1)/w and bni = 1 for
i ≥ 2. So that, condition (4.2) does not hold. Condition (4.2) appears too stringent, but
the following corollary shows a situation where it holds.
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Corollary 4.2.1. Let {ai}i≥1 be a sequence of zeros and ones. Assume that the length of
any run of ones is bounded by a value M. Then, for any j = 1, . . . , n,
b2jn
n∑
j=1
b2jn
= Θ
(
1
n
)
where {bjn}j=1,...,n are the coefficients of (4.8).
Proof. For each value n, fix a value i = 1 . . . n − 1 and denote Rk the length of the kth
run of ones after the position i of An and Lk the length of the kth run of zeros before the
kth run of ones after the position i of An. Let t the number of runs of ones from the ith
position until the nth position. Then, if ai = 0, from (4.8) we have
|bin| = 1
w
(
R1 + (1− 1
w
)L1R2 + · · ·+ (1− 1
w
)
∑t−1
i=1 LiRt
)
≤ M
w
(
1 + (1− 1
w
)L1 + · · ·+ (1− 1
w
)
∑t−1
i=1 Li
)
≤ M
(
1− (1− 1
w
)n+1
)
≤ M.
So for each n and for any i = 1, . . . , n, |bin| is a bounded value and the result follows.
Observe that condition (4.2) deals with a non finite sequence of responses. However, in
a clinical trial, a finite number of patients participate and, so, we have a finite sequence of
responses An. Although Corollary 4.2.1 gives a quite realistic condition, it also relies on the
assumption that an infinite sequence of responses is available. In [60] the same situation
happens and to determine how a typical response sequence behaves, An is considered a
realization of a Bernoulli trial of length n, that is, a sequence of random variables Yi, i =
1, . . . , n independent and identically distributed with P (Yi = 1) = p and P (Yi = 0) = q.
For each n, we define Bnj as bnj in (4.8) via the sequence {Yi} , i = 1, . . . , n instead
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of An. Then, for each n and 1 ≤ j ≤ n
Bnj = Yj − 1− Yj
w
n∑
i=j+1
(
1− 1
w
) i−1∑
r=j+1
(1− Yr)
Yi (4.18)
where
∑b
a = 0 when b < a.
It is not difficult to see from (4.18) that for each n and 1 ≤ j ≤ n
Bnj = Yj − 1− Yj
w
Fj∑
r=1
Ljr(1−
1
w
)r−1.
where, Fj is the number of failures from the (j + 1)-th patient up to, and including, the
n-th patient, and Ljr is the number of successes between the r-th and (r + 1)-th failures,
so Ljr = 0 when both zeros are consecutive. If Yn = 1, then L
j
Fj
is equal to the number of
ones between the last failure and n and otherwise, is equal to zero.
Let Ln be the longest run of successes in n independent Bernoulli trials with success
probability p. It is well-known that Ln/log1/pn → 1, almost surely, see, for instance,
section 2.2.5 in [4]. On the other hand,
∑n
j=1B
2
nj ≥
∑n
j=1 Yj and, for a constant C
B2nj < CL
2
n. So that, for any 0 < p < 1,
max1≤j≤nB2nj
n∑
j=1
B2nj
→ 0, a.s.
We only have to elucidate if, for any 0 ≤ p ≤ 1, condition (4.2) holds, that is, if the
sequence {Bn} is Θ
(
1
n
)
, where, for each n,
Bn =
max1≤j≤nB2nj
n∑
j=1
B2nj
.
For w = 1, it is immediate to prove that {Bn} is Θ
(
1
n
)
for any 0 < p < 1. However,
small values of w entail large asymptotic selection bias as measured in [26]. When w ≥ 2,
intensive simulation studies have been carried out and support that {Bn} is Θ
(
1
n
)
.
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Lemma 4.2.2. The triangular array of random variables {Bnj : n ≥ 1, 1 ≤ j ≤ n}
satisfies the following properties:
a) For each n and 1 ≤ j ≤ n we have that
E[Bnj ] = p
(
1− q
w
)n−j
.
b) Let A1 = p+ q
(
1− 1
w
)2
and A2 = 1− q
w
. For each n and 1 ≤ j ≤ n we have that
E[B2nj ] = p+
p
w2
1−An−j1
1−A22
+ 2pw
n−1∑
r=j+1
Ar−j−11 (1−An−r2 )
 .
c) When n→∞,
n∑
j=1
E[Bnj ]→ pw
q
.
d) When n→∞,
n∑
j=1
E[Bnj ]/n→ 0 and
n∑
j=1
E[B2nj ]/n→ p+
pq + 2p2w
w2(1−A1)
Proof. Taking expectations in the definition of Bnj in (4.18), we get
E[Bnj ] = p− qp
w
n∑
i=j+1
E
[
(1− 1
w
)
∑i−1
r=j+1(1−Yr)
]
= p− qp
w
n∑
i=j+1
i−1∏
r=j+1
E
[(
1− 1
w
)(1−Yr)]
.
Considering that Yr are Bernoulli variables, E
[(
1− 1w
)(1−Yr)] = p + q (1− 1w) = 1 − qw ,
so
E[Bnj ] = p− qp
w
n∑
i=j+1
(
1− q
w
)i−j−1
= p− qp
w
n−j−1∑
i=0
(
1− q
w
)i
= p− qp
w
1− (1− qw)n−j
1− (1− qw) = p
(
1− q
w
)n−j
,
and part a) is proven. For part b), using (4.18) we can express B2nj as
B2nj = Yj −
1− Yj
w2
 n∑
r=j+1
lr
2 ,
94
where lr = Yr
(
1− 1w
)∑r−1
s=j+1(1−Ys) = Yr
r−1∏
s=j+1
(
1− 1
w
)1−Ys
.
Now,
E[B2nj ] = p+
q
w2
 n∑
r=j+1
E
[
l2r
]
+ 2
∑
t>nr=j+1,n
E[lrlt]
 , (4.19)
E
[
l2r
]
= E
Yr r−1∏
s=j+1
(
1− 1
w
)2(1−Ys)
= p
r−1∏
s=j+1
[
p+ q
(
1− 1
w
)2]
= p
[
p+ q
(
1− 1
w
)2]r−j−1
,
taking into account the independence between Yr and the product. Computing all the
summation,
n∑
r=j+1
E
[
l2r
]
= p
n∑
r=j+1
[
p+ q
(
1− 1
w
)2]r−j−1
= p
n−j−1∑
r=0
[
p+ q
(
1− 1
w
)2]r
= p
1−
[
p+ q
(
1− 1w
)2]n−j
1−
[
p+ q
(
1− 1w
)2] = pq 1−
[
p+ q
(
1− 1w
)2]n−j
1− (1− 1w)2 (4.20)
We follow a similar procedure for E[lrlt]. Assuming t > r,
E[lrlt] = E
Yr r−1∏
s=j+1
(
1− 1
w
)(1−Ys)
Yt
t−1∏
s=j+1
(
1− 1
w
)(1−Ys)
= E
Yr (1− 1
w
)r r−1∏
s=j+1
(
1− 1
w
)2(1−Ys)
Yt
t−1∏
s=r+1
(
1− 1
w
)(1−Ys)
= E
[
Yr
(
1− 1
w
)Yr]
E
 r−1∏
s=j+1
(
1− 1
w
)2(1−Ys)E [Yt t−1∏
s=r+1
(
1− 1
w
)(1−Ys)]
,
due to the independence of the different responses. Calculating the expectations as above,
E[lrlt] = p
[
p+ q
(
1− 1
w
)2]r−j−1
p
[
p+ q
(
1− 1
w
)]t−r−1
= p2
[
p+ q
(
1− 1
w
)2]r−j−1 (
1− q
w
)t−r−1
.
95
Calculating the whole summation,
n−1∑
r=j+1
n∑
t=r+1
E[lrlt] =
n∑
r=j+1
n∑
t=r+1
p2
[
p+ q
(
1− 1
w
)2]r−j−1 (
1− q
w
)t−r−1
=
n−1∑
r=j+1
p2
[
p+ q
(
1− 1
w
)2]r−j−1 n−r−1∑
t=0
(
1− q
w
)t
=
n−1∑
r=j+1
p2
[
p+ q
(
1− 1
w
)2]r−j−1 1− (1− qw)n−r
q
w
=
wp2
q
n−1∑
r=j+1
[
p+ q
(
1− 1
w
)2]r−j−1 [
1−
(
1− q
w
)n−r]
(4.21)
Plugging (4.21) and (4.20) into (4.19) and denoting A1 = p + q
(
1− 1w
)2
A2 = 1 − qw
we get the expression in b),
E[B2nj ] = p+
p
w2
 1−An−j1
1− (1− 1w)2 + 2wp
n−1∑
r=j+1
Ar−j−11
[
1−An−r2
]
For part c),
n∑
j=1
E[Bnj ] =
n∑
j=1
p
(
1− q
w
)n−j
= p
n−1∑
j=1
(
1− q
w
)j
and taking limits the result is direct. The last part follows straightforwardly noting that
E[Bnj ]→ 0 and taking a cesaro-type limit.
By assuming that a Bernoulli trial gives the set of responses, we can give more explicit
expressions about the random variable Sn.
Proposition 4.2.2. Consider that a Bernoulli trial of length n and success probability p
generates the sequence of responses in a clinical trial where the allocations are made with
a Klein design with, initially, w > 1 balls of each color. Then, as n→∞
E [V ar[Sn]]
n
→
(
p+
pq + 2p2w
w2(1−A1)
)(
1− 1
2w
)
Proof. Let Yn = σ(Y1, . . . , Yn). Observe that An is a specific realization of the Bernoulli
trial. Let Dj =
w
2
(1− 2
w
)
∑j−1
i=1 (1−Yi). From (4.11) we have that
E[V ar[Sn]] =
n∑
j=1
E[Dj ]E[B2nj ] (4.22)
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where the equality follows from the fact thatDj is Yj−1-measurable andB2nj is σ(Yj , ..., Yn)-
measurable.
It is easy to see that E[Dj ] = 1− 12w
(
1−
(
1− 2
w
)j)
and from Lemma 3.2 the result
follows straightforwardly.
Remark 4.2.2. The study of central limit theorems for non-homogeneous chains is not
a closed problem and, up to our knowledge, there is not in the literature any theorem
in which our chain fits. On the topic of central limit theorems for non-homogeneous
Markov chains, [55] is an updated reference that explains the state of the art and gives
new sufficient conditions for the existence of a central limit theorem for
n∑
i=1
Wi, 1/V ar
[
n∑
i=1
Wi, 1
]
.
Those conditions are based on the maximal coefficient of correlation ρn,1. For {Wn,1},
following [55] we have that
ρn, 1 = max1≤k≤n−1ρ(Wk,1, Wk+1,1).
Assuming the conditions of Proposition 4.1.2 we have to compute Cov(Wk,1, Wk+1,1).
Using the decomposition of Wk,1 in (4.1),
Cov(Wk,1, Wk+1,1) = V ar(Wk,1)− Cov
(
Wk,1, (1− ak+1) δ˜k+1
)
Using Proposition 2.2.1
Cov
(
Wk,1, (1− ak+1) δ˜k+1
)
= Cov
(
Wk,1, E
[
(1− ak+1) δ˜k+1|Fk
])
= Cov
(
Wk,1, (1− ak+1) Wk,1 − 1
w
)
=
1− ak+1
w
V ar(Wk,1)
So, we get the next relationship,
Cov(Wk,1, Wk+1,1) = V ar(Wk,1)
(
1− 1− ak+1
w
)
.
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As if ak = 1 then V ar(Wk,1) = V ar(Wk−1,1), from the behavior of the chain, in case of
success the distribution does not change. Then, assume that for some value n0, an0+1 = 1.
This condition is not stringent, because in some step a success is expected. Therefore, we
obtain that ρ(Wn0,1, Wn0+1,1) = 1. So that, ρn, 1 = 1 for any n ≥ n0; and the conditions
on [55] to obtain a central limit theorem for {Wn,1} do not hold. So, the most recent
central limit theorem for non-homogeneous Markov chains is not valid for our purposes.
Remark 4.2.3. Remember that
Sn = Wn,1 − w + ∆n
where ∆n = 2Nn,1 − n and {Wn,1 − w} is a bounded sequence, given an appropriate
sequence {kn} of positive numbers which grows to infinity we obtain
Sn√
kn
=
Wn,1 − w√
kn
+
∆n√
kn
,
so that, in the conditions of Theorem 4.2.1, we obtain a central limit theorem for
2n√
kn
(
Nn,1
n
− 1
2
)
.
Now, the non-homogeneous Markov Chain {Wn,1} has a Central Limit Theorem, fol-
lowing the same reasoning of Proposition 4 in [26] where a central limit theorem is obtained
for the non-conditioned process {Wn,1}.
4.3 Simulation study
The quality of the normal approximation of the p-values has been studied via Monte
Carlo simulation and Table 4.3 gives a summary of the results. For a sequence of patients’
responses of length n, generated with a Bernoulli distribution of parameter p, the design
is run 15000 times, generating 15000 values of Sn√
kn(1− 12ω )
. The percentage, r(i), of these
values smaller than the i-percentile of the normal standard distribution is calculated.
To obtain the precision of the estimator, this procedure is repeated 1000 times for i =
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80, 90, 95 and 99 and for sample sizes n = 50, 150 and 500. The mean values (and
standard deviations) of r(i) are displayed in Table 4.3.
These values give us an accurate information about how close are the tails of both
distributions. We observe that the proportion r(i) is close to i, even for n = 50 and for
the most extreme percentile i = 99. As could be expected, the approximation is better for
greater values of n.
Table 4.1: Proportion of values of the test-statistic Sn/
√
kn(1− 12ω ) lower than the i-
percentile of the standard normal distribution.
i = 80 i = 90
p n = 50 n = 150 n = 500 n = 50 n = 150 n = 500
0.9 0.7914 0.7939 0.7971 0.8934 0.8956 0.8981
(0.0201) (0.0084) (0.0044) (0.0135) (0.0056) (0.0031)
0.5 0.7945 0.7978 0.7996 0.8957 0.8983 0.8996
(0.0279) (0.0142) (0.0080) (0.0180) (0.0091) (0.0052)
0.1 0.7917 0.7985 0.7976 0.8930 0.9004 0.8989
(0.0522) (0.0413) (0.0215) (0.0367) (0.0260) (0.0146)
i = 95 i = 99
p n = 50 n = 150 n = 500 n = 50 n = 150 n = 500
0.9 0.9466 0.9476 0.9493 0.9899 0.9902 0.9904
(0.0081) (0.0036) (0.0021) (0.0023) (0.0011) (0.0009)
0.5 0.9482 0.9493 0.9500 0.9908 0.9904 0.9901
(0.0106) (0.0055) (0.0032) (0.0027) (0.0016) (0.0011)
0.1 0.9521 0.9500 0.9497 0.9917 0.9909 0.9905
(0.0205) (0.0161) (0.0083) (0.0059) (0.0038) (0.0023)
Chapter 5
Covariates and the Klein urn
design
Covariates or prognostic factors can give important information about patients and can
have influence in patient’s response to the treatment. An imbalance between covariate
levels could produce a bias in the study. Even if randomization itself protects against
these imbalances, see [63] Chapter 5, due to the asymptotic nature of this property, in
moderate sample sizes some imbalance could appear, biasing the study. Different solutions
have been presented in order to avoid or mitigate this problem. For instance, a technique
deals with the inclusion of covariates in the design of the trial. In Chapter 4 of [63] and
in [65] good reviews of the use of covariates in adaptive designs can be seen.
If we want to use the patient’s covariates in the allocation rule in an urn-based design
it seems natural to make a stratification and assign a different urn to each stratum. The
Klein urn design has been introduced as a clinical trial design without taking into account
covariates. In this chapter we study how to introduce covariate information with the
goal of improving the inferential procedure. A stratified version of the Klein urn design
is presented here, and some basic properties are studied. Besides, we consider a model
that relates the observed responses with the treatment applied and with some patient’s
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covariates. The main difficulty is the dependence between the error terms in the model
due to the adaptive allocation process. So, consistency and asymptotic normality of the
estimators need to be assessed. Finally, a study is made via simulation, comparing a
classical Wald test, a randomization test and a test based on the model.
5.1 The stratified response-adaptive Klein urn design
A clinical trial with two treatments is considered. We assume that patients arrive sequen-
tially and their covariate information is available before they are allocated to a treatment.
With this information the stratification is done. Each stratum can be seen as a combina-
tion of levels of relevant covariates. For instance, it could be assumed that there are M
covariates (or prognostic factors) H = (H1, . . . , HM ), with m1, . . . ,mM different levels,
respectively, and therefore the number of strata is K =
∏M
i=1mi. The indicator function
of the n-th patient’s stratum is denoted by
pink =
 1, n-th patient belongs to the k-th strata;0, otherwise.
We assume that {pink} are independent Bernoulli random variables with mean pik,
where pik > 0, k = 1, . . . ,K and
∑K
k=1 pink = 1. Patients are allocated to a treatment
using a different urn for each stratum. When a patient that belongs to stratum k arrives, a
ball is drawn from the urn k, and the patient is allocated to the corresponding treatment.
For the sake of clarity, in this chapter the indicator function of the n-th patient’s treatment
is δnj , j = 1, 2. Relating with the indicators used in the previous chapters, δn1 = δn and
δn2 = 1− δn. Note that its distribution depends on the stratum of the patient.
We assume that the response is observed before the next patient arrives. We denote
by Znkj the response of the n-th patient to the treatment j, when this patient belongs to
stratum k. Note that only one of the possible 2 ×K responses is really observed. If this
response is dichotomous (success or failure) with success probability pkj , we denote the
failure indicator as Fnkj = 1 − Znkj . In general, the indicator of failure can be defined
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as Fnkj = g(Xnkj) were the function g can be seen as a discretization to failure/success
of, maybe, a continuous response Xnkj . We assume that {Fnkj} are Bernoulli random
variables with mean qkj = 1 − pkj . The replacement policy is the usual one in the Klein
urn: If the treatment is a failure, we put a ball of the other type instead of the extracted
ball; otherwise, we replace the extracted ball and the urn remains unchanged.
Therefore, the urn is updated with the following replacement matrix
type 1 type 2
↓ ↓
Get type 1 ball →
Get type 2 ball →
Ri =
 −Fnk1 Fnk1
Fnk2 −Fnk2

This procedure will be called stratified Klein urn design. If we have allocated n pa-
tients, we denote the number of patients in stratum k assigned to treatment j as
Nnkj =
n∑
i=1
δijpiik .
We denote the total number of patients in stratum k as Nnk· and the total number of
patients assigned to treatment j as Nn·j ,
Nnk· = Nnk1 +Nnk2 ; Nn·j =
K∑
k=1
Nnkj .
For instance, consider a case with two covariates with two levels each, this would lead
to a scenario with 2× 2 = 4 strata. Here we show a displayed table of n allocations with
4 strata.
Stratum Treatment 1 Treatment 2 Total
1 Nn11 Nn12 Nn1·
2 Nn21 Nn22 Nn2·
3 Nn31 Nn32 Nn3·
4 Nn41 Nn42 Nn4·
Total Nn·1 Nn·2 n
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Due to the heterogeneity between patients in the different strata, the probability of success
also can be different. So, the behavior of the urns linked to each stratum could be different.
The limit proportion of treatment 1 allocations can be computed for each stratum and
using these quantities the overall treatment allocation proportion is also computed.
Proposition 5.1.1. Assume that the stratified Klein urn design is applied. Then, for
each stratum k in 0, ...,K,
Nnk.
n
→ pik a.s.
Nnk1
Nnk·
→ ak1 := qk2
qk1 + qk2
a.s.
Nn·1
n
→
K∑
k=1
ak1pik a.s.
Proof. Observe that {pink} are independent Bernoulli random variables with mean pik, for
each stratum k. So, from the classical strong law of large numbers,
Nnk·
n
=
∑n
i=1 piik
n
→ pik a.s. (5.1)
The probability of assigning each stratum, pik, is strictly positive so, Nnk., the number
of times that each stratum is assigned (i.e. the number of patients in each urn) goes to
infinite. Moreover, as these random variables, {piik}, are independent, then each urn works
independently from the others, and we can apply the theory of Chapter 2 in each stratum.
Being qk1 the probability of failure of treatment 1 in the k-th stratum, Proposition 2.4 in
Chapter 2 gives
Nnk1
Nnk.
→ qk2
qk1 + qk2
= ak1, a.s. (5.2)
Finally, combining (5.1) and (5.2), we get the convergence of the total proportion of
treatment 1 allocations,
Nn.1
n
=
∑K
k=1Nnk1
n
=
K∑
k=1
Nnk1
Nnk.
Nnk.
n
→
K∑
k=1
qk2
qk1 + qk2
pik .
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The stratification also permits doing stratified inference analysis, defining the usual
estimators for each stratum. We denote the proportion of successes of treatment j in
stratum k until patient n as
pˆnkj =
1
Nnkj
n∑
i=1
Zikjδijpiik .
The average of successes for treatment j can be expressed as
pˆn.j =
∑K
k=1Nnkj pˆnkj
Nn.j
.
If we consider the case with non dichotomous responses, then Xikj are quantitative
random variables with mean µkj . We denote the average of treatment j in stratum k until
patient n as
µˆnkj =
1
Nnkj
n∑
i=1
Xikjδijpiik .
Then, the average of treatment j can be expressed as
µˆn.j =
∑K
k=0Nnkjµˆnkj
Nn.j
.
In the following proposition the limit behavior of these estimators is obtained.
Proposition 5.1.2. Assume that the stratified Klein urn design is applied. If the responses
Zikj are independent Bernoulli random variables with mean pkj for each stratum k in
1, ...,K and treatment j = 1, 2, then
pˆnkj → pkj a.s.
pˆn.j → p.j :=
∑K
k=1 pikakjpkj∑K
m=1 pimamj
a.s.√
Nnkj(pˆnkj − pkj) → N(0, pkjqkj) [D]
√
n(pˆnkj − pkj) → N(0, pkjqkj/(akjpik)) [D]
If the responses Xikj are independent non-binary random variables with mean µkj and
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variance V ar(Xnkj) = σ2kj for each stratum k in 1, ...,K and treatment j = 1, 2, then
µˆnkj → µkj a.s.
µˆn.j → µ.j :=
∑K
k=1 pikakjµkj∑K
m=1 pimamj
a.s.√
Nnkj(µˆnkj − µkj) → N(0, σ2kj) [D]
√
n(µˆnkj − µkj) → N(0, σ2kj/(akjpik)) [D]
Proof. As the probability of assigning stratum k, pik k = 1, ...,K, is strictly positive, then
Nnk. →∞. Applying Proposition 3 in [26] or Proposition 2.3 in Chapter 2, we know that
Nnkj →∞ for any pair (k, j). So, in each stratum treatment 1 and 2 are applied infinite
times. Theorem 1 in [11] could be applied for each stratum. Then, strong laws can be
applied to these estimators and therefore,
pˆnkj → pkj a.s. .
For the average of successes in treatment j, we have to compute the proportion of
treatment 1 allocations that are in the k-th stratum and
Nnkj
Nn.j
=
Nnkj
Nnk.
Nnk.
n
n
Nn.j
→ akjpik 1∑K
m=1 pimamj
using the three convergences of Proposition 5.1.1. Then, the overall limiting proportion
can be computed
pˆn.j =
∑K
k=1Nnkj pˆnkj
Nn.j
=
K∑
k=1
Nnkj
Nn.j
pˆnkj →
∑K
k=1 pikakjpkj∑K
m=1 pimamj
The adaptive central limit theorem also holds for each stratum,
√
Nnkj (pˆnkj − pkj)→ N(0, pkjqkj) [D] .
Noting that
n
Nnkj
=
n
Nnk.
Nnk.
Nnkj
→ 1
akjpij
a.s., if we replace
√
Nnkj by
√
n, the central
limit still holds adjusting the variance,
√
Nnkj (pˆnkj − pkj)→ N(0, pkjqkj) [D] .
The results for the case of non-dichotomous responses follow with an analogous argu-
mentation.
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Assuming a population model, conventional inference could be done. This inference
could be stratum by stratum or a global test encompassing all of them. Using a test
statistic that includes the covariates that have been used in the randomization procedure
is recommended in [69] and [1].
Remark 5.1.1. Another way to do inference is the use of stratified randomization tests,
as in Chapter 8 in [63]. The main idea is to use the randomization test presented in
Chapter 3 in each stratum and then combine all these statistics in a common statistic.
That is, let Snk =
∑Nnk.
i=1 ai(k)δ˜ik be the test statistic in the k-th stratum, being ai(k) the
fixed response of the i-th patient in the k-th stratum. Then, a global test is defined as
Sn =
K∑
j=1
ωjSnj ,
where the ωj are weights which define the importance of the different strata, where the
weights ωj are usually the proportion of patients in each stratum.
5.2 Generalized linear adaptive models
When we assume a model that relates the response with some covariates, the effect of the
treatments can be included in this model. It is interesting to study how the use of an
adaptive design affects the estimation of the parameters. The generalized linear models
(GLM) are a general framework for this study. In such models, it is assumed that the
distribution of the responses belongs to the exponential family, and these responses are
related, via a link function, with a linear function of the covariates, that is, with a linear
predictor. GLM were introduced in [54] and a detailed study of their properties can be
seen in [48].
Dichotomous responses, success or failure, are being considered in our study, so, the
canonical link function is the logistic function. However, as we are using an adaptive design
to allocate patients, the classical assumption of independence or incorrelation do not hold,
so, we have that the usual properties of the estimators are not guaranteed, therefore, a
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more detailed study is needed.
Let Yn be the dichotomous random variable indicating the response of the n-th patient,
with Yn = 1 when the treatment is successful and Yn = 0 when the treatment fails. Let
the natural filtration be Fn−1 = σ (Zn−1,Gn,Hn), where Zn, Gn and Hn are defined as
in section 1.1 . Then, Yn is Fn-measurable and the regressors are Fn−1-measurable. We
denote
E[Yn|Fn−1] = µ(βtxn) = e
βtxn
eβtxn + 1
= µn
V ar[Yn|Fn−1] = v(µn) = e
βtxn
(eβtxn + 1)2
= vn .
where µ(·) is the link function, β is the vector of parameters and xn is the vector of
regressor variables and, therefore, η = βtxn is the linear predictor. The regression relation
has now the form
Yn = µ(βtxn) + n , (5.3)
where n = Yn − E[Yn|Fn−1] form a martingale difference sequence.
For the linear predictor η = βtxn, three different models are considered: (A) assumes
a linear growing effect on the levels of the strata, (B) uses a parameter for each stratum
and (C) uses a parameter for each treatment-stratum interaction.
η =

2∑
j=1
µjδnj + γ
K∑
k=1
kpink (A) ,
2∑
j=1
µjδnj +
K∑
k=1
γkpink (B) ,
2∑
j=1
µjδnj +
2∑
j=1
K∑
k=1
γkjδnjpink (C) .
In order to avoid multicollinearity and to ensure the invertibility of the design matrix
Dn =
∑n
i=1 xix
t
i, some changes have been made in models (B) and (C). In model (B),
the indicators of treatment 2 and covariate K have been dropped and so the intercept α
reflects this baseline status: to be in treatment 2 and covariate K. In model (C) the effect
of covariate K has been dropped, and the effect of this covariate is taken as the baseline
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effect in the coefficients of the treatments.
η =

2∑
j=1
µjδnj + γ
K∑
k=1
kpink (A) ,
α+ µδn1 +
K−1∑
k=1
γkpink (B) ,
2∑
j=1
µjδnj +
2∑
j=1
K−1∑
k=1
γkjδnjpink (C) .
In generalized linear models, in order to estimate the parameters, maximum likelihood
estimation is used. Nevertheless, the specification of the likelihood function is not easy
in many cases. If the link function is not correctly determined, it is imposible to give
an explicit formula for the likelihood. Other common problem in order to determine
the likelihood function is the dependence between observations, which could make very
difficult its computation. This is the case of adaptive designs. A plausible alternative is
the construction of the quasi-likelihood function, presented in [72]. For more details of
the construction and characteristics of these function we refer to [48]. We can define the
quasi-likelihood estimator, βˆn, as the solution of the equation
n∑
i=1
g(βtxi)xi{Yi − µ(βtxi)} = 0 ,
where g(·) is usually Dµ(·)/v(·). If the link function is the canonical one, g(·) becomes
the identity, so the quasi-likelihood equation stands in this form,
n∑
i=1
xi{Yi − µ(βtxi)} = 0 .
Let λmin(A) and λmin(A) be, respectively, the minimum and maximum eigenvalue of
the square matrix A. Then, the following technical lemma is introduced.
Lemma 5.2.1. For models (A), (B), (C) of the lineal predictor, the next results are
fulfilled:
λmin(Dn)→∞ , (5.4)
lim inf
n→∞
λmin(Dn)
λmax(Dn)1/2(log λmax(Dn))1/2+α
for some α > 0 (5.5)
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Proof. We compute the design matrix Dn and its determinant for each model.
Model (A): Denoting Fn =
∑K
k=1 kpink and Fnj =
n∑
i=1
δijFi for j = 1, 2 then,
Dn =

Nn.1 0 Fn1
0 Nn.2 Fn2
Fn1 Fn2
n∑
i=1
F 2i

|Dn| = Nn.1Nn.2
(
n∑
i=1
F 2i −Nn.2F 2n1 −Nn.1F 2n2
)
Model (B):
Dn =

n Nn.1 Nn1. . . . . . . NnK−1.
Nn.1 Nn.1 Nn11 . . . . . . NnK−11
Nn1. Nn11 Nn1. 0 . . . 0
...
... 0
. . . . . . 0
...
... 0
. . . . . . 0
NnK−1. NnK−11 0 . . . 0 NnK−1.

|Dn| =
K∏
i=1
Nni.
(
Nn.1 −
K∑
k=1
N2nk1
Nnk.
)
Model (C):
Dn =

Nn.1 0 Nn11 . . . NnK−11 0 0 0
0 Nn.2 0 0 0 Nn12 . . . NnK−12
Nn11 0 Nn11 0 . . . . . . . . . 0
...
... 0
. . . 0 . . . . . . 0
NnK−11 0 0 0 NnK−11 0 . . . 0
0 Nn12 0 . . . 0 Nn12 0 0
...
... 0 . . . . . . 0
. . . 0
0 NnK−12 0 . . . . . . . . . 0 NnK−12

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|Dn| =
K∏
i=1
Nnk1Nnk2
For model (A), the lemma is proven in Lemma 3.1 in [53]. For models (B) and (C),
all the elements of the Dn = {dij(n)} matrix are Θ(n) functions, so, we can ensure the
irreducibility of the matrix and apply Theorem 1.5 in [68], which guarantees the next
inequality,
min
i
 l∑
j=i
dij(n)
 ≤ λmax(Dn) ≤ max
i
 l∑
j=i
dij(n)
 .
It follows that λmax(Dn) ∈ Θ(n). Besides, |Dn| ∈ Θ(nl) in models (B) and (C), with
l = dim(Dn). Using
(λmin(Dn))l−1λmax(Dn) ≤ |Dn| ≤ (λmax(Dn))l−1λmin(Dn),
it holds that λmin(Dn) ∈ Θ(n) and (5.4) and (5.5) follow straightforwardly.
In the next proposition, the properties of the estimators βˆn are studied under a general
stratified design and the canonical link function.
Proposition 5.2.1. Assume that n patients have been allocated in the treatments with
a stratified design. Let Nnkj the total number of patients, up to the n-th patient, in the
stratum k allocated in treatment j, with k = 1, ...,K and j = 1, 2.
Assume that patients’ responses {Yn} satisfy a generalized linear model (5.3) where µ
is the logistic function and β is as in model (A), (B) or (C).
Assume also that for each pair k and j, there exists a vector uk = (uk1, uk2), with
uk1 > 0 and uk2 > 0 such that
Nnkj/n→ ukj , k = 1, ... ,K , j = 1, 2. (5.6)
Let βˆn be the MQLE of the vector of parameters β, then, as n→∞
βˆn → β, a.s.
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V −C/2n Vn(βˆn − β)t → N(0, I) [D] ,
with
Vn =
n∑
i=1
xtiH(β
txi))xi
where H(t) is the derivative of µ evaluated in t ∈ R and V C/2n is the lower triangular
matrix of the Cholesky square root.
Proof. The result follows if conditions in Theorem 2 in [76] hold.
A1) For any t ∈ R, Σ−1 > 0, detH(t) 6= 0, each element of Σ−1 > 0 is continuously
differentiable and µ(t) is twice continuously derivable.
A2∗) With probability 1, supi≥1 ‖xi‖ <∞, λmin(Dn)→∞ and
lim infn→∞
λmin(Dn)
λmax(Dn)1/2(log λmax(Dn))1/2+α
for some α > 0.
A3∗) For each i ≥ 1, yi is Fi measurable, xi is Fi−1 measurable. With probability 1,
E(yi | Fi−1) ≡ µ(βtxi) and supi≥1E(‖i‖ | Fi−1) <∞
A4∗) With probability 1, Cov(i|Fi−1) > cI and supi≥1E(‖i‖r | Fi−1) for some r > 2.
Besides, there exists a non-random positive definite symmetric matrix Fn such that
F
1
2
n VnF
1
2
n → I in probability.
Conditions A1 and A3∗ are immediate to check for (5.3) under the three models, due to
the definition of the logistic model and the boundedness of the estimators. Condition A2∗
is a direct conclusion of Lemma 5.2.1.
For condition A4∗, from the definition of the error terms, Cov(i|Fi−1) > cI and
supi≥1E [‖i‖r|Fi−1] < ∞ are direct. As Vn =
∑n
i=1 vixix
t
i, being vi = H(β
txi) =
eβ
txi
(eβ
txi+1)2
, Vn is symmetric and definite positive. If Vn/n→ C a.s. when n→∞ and ‖C‖ 6=
0, then C is also symmetric and definite positive. So, there exits as symmetric and positive
matrix F such that C = F 1/2F 1/2. Defining Fn = nF , we have that F
−1/2
n VnF
−1/2
n → I
as n→∞.
We prove now that Vn/n→ C a.s. when n→∞ and ‖C‖ 6= 0. Observe that once δi1
and Fi are known, vi does not depend on i and we denote as vkj the value of vi if the i-th
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patient has prognostic factor k and is allocated to treatment j. Under model (A) we have
that
Vn =

n∑
i=1
viδi1 0
n∑
i=1
viδi1Fi
0
n∑
i=1
viδi2
n∑
i=1
viδi2Fi
n∑
i=1
viδi1Fi
n∑
i=1
viδi2Fi
n∑
i=1
viF
2
i

. (5.7)
The analysis of the convergence is particular for each element of the matrix. We illustrate
the procedure with
n∑
i=1
viδi1Fi and the convergence of the other elements will follow with
the same reasoning. Knowing δi1 and piik, vi is Vk1, so
n∑
i=1
viδi1Fi =
n∑
i=1
K∑
k=1
viδi1kpiik =
K∑
k=1
vk1Nnk1 . (5.8)
Since Nnk1/n→ uk1 > 0, 1n
∑n
i=1 viδi1Fi also converges.
Reasoning in the same way, the results also follow under model (B) and model (C).
Corollary 5.2.1. If the stratified Klein urn design has been applied, under models (A),
(B) and (C), the MQL estimators βˆn are strongly consistent and asymptotically normal.
Proof. Under the stratified Klein urn design, using Proposition 5.1.1, the convergence
Nnij/n→ uij is ensured, and then Proposition 5.2.1 follows directly.
This fact permits the use of these estimators in the inferential study via simulation in
the next section.
5.3 Simulation Study
The previous section was focused on the theoretical analysis of the properties of the MQL
estimators in a generalized linear model. Now, an inferential comparative study based on
simulation is presented, in order to test the hypothesis of equality between both treat-
ments. The comparative study is made among the designs studied in Chapter 3, complete
randomization, Efron’s design, PTW design, Klein urn design, DBCD design with α = 2
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and ERADE design with α = 7. We are going to follow two different approaches. On the
one hand, a population model is assumed with dichotomous responses. Then, a general-
ized linear model, more precisely a logistic model, is considered for these responses, as in
the previous section. Besides, a time trend factor is introduced, defining a covariate Fn
with three levels, values 1, 2 or 3. So the model stands as
logit(yn) = µ1δn1 + µ2(1− δn2) + γFn (5.9)
which corresponds with model (A) of the previous sections. Our target is to estimate the
difference of the effect of the treatments,
H0 : µ1 − µ2 = 0, H1 : µ1 − µ2 6= 0.
The test statistic is defined as Tglm = (1, −1, 0)βˆ = µˆ1 − µˆ2. To ensure the asymptotic
normality of these estimators, note that under a population model, all the designs con-
sidered satisfy that, almost surely, Nn.i/n→ ρ, where 0 < ρ < 1 varies depending on the
design. This result is (5.6) condition .
On the other hand, assuming a randomization model, RBI . The procedure is the same
as the one presented in Chapter 3. The null hypothesis is that both treatments behave
equally. The test statistic is Tn = Sn,1/Nn,1 − Sn,2/Nn,2, which is the difference of the
proportion of successes in each treatment. This statistic can be seen as a randomization
version of the classical test of difference of means.
In Table 5.1, µ2 = 0.1, β = 1 and the following two situations: µ1 = 0.1, when there
is not difference between treatments and the null hypothesis is true, and µ1 = 2.1, when
the null hypothesis is false. The covariate {Fn} is simulated as a sequence of independent
and identically distributed uniform random variables on the set {1, 2, 3}. We consider
n = 50, 100, 200 patients. The responses are simulated using the GLM for both cases.
We make asymptotic inference for the GLM estimators following [76] and the RBI as in
Table 3.5.
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Table 5.1: Proportion of rejections with the randomization test and test statistic T (Monte
Carlo estimations of the p-values with 2,500 runs) and the classical parametric inference
with the MQL estimators of the GLM.
n = 50 n = 100 n = 200
µ1, µ2, β D T GLM T GLM T GLM
0.1, 0.1, 1
CR 0.044 0.019 0.037 0.032 0.052 0.046
Efron 0.040 0.016 0.038 0.034 0.0548 0.050
PTW 0.061 0.041 0.053 0.052 0.038 0.39
Klein 0.040 0.020 0.062 0.060 0.049 0.052
DBCD2 0.036 0.017 0.056 0.049 0.056 0.048
ERADE7 0.042 0.026 0.049 0.051 0.060 0.051
2.1, 0.1, 1
CR 0.263 0.019 0.580 0.230 0.904 0.760
Efron 0.198 0.018 0.520 0.217 0.867 0.763
PTW 0.221 0.047 0.480 0.288 0.852 0.798
Klein 0.228 0.058 0.559 0.260 0.825 0.758
DBCD2 0.235 0.025 0.587 0.258 0.877 0.747
ERADE7 0.210 0.034 0.561 0.289 0.863 0.767
Observe that the randomization test performs better than the standard test for pa-
rameters in a GLM model with n = 50 and n = 100 sample sizes. For n = 200 results
are quite similar for both inferential procedures. We do not appreciate a different be-
havior depending on the design applied. The bad figures for the GLM estimation can
be explained because, as stated before, they are based on the asymptotic normality of
the estimators and higher values of n are needed. Nevertheless, for larger sample sizes, as
n = 200, the results improve because conditions in [28] hold for this model and asymptotic
normality is true even if an adaptive design has been applied for randomization. So that,
RBI seems a fruitful inference procedure when tendency can be expected in the responses
and randomization with adaptive designs is applied. Observe that in order to obtain the
distribution of Tn nor a population model, neither an statistical model are assumed. Be-
sides this, a simulation study shows that for small to moderate sample sizes the inference
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based on Tn is more powerful than the inference based on Tglm even if the population
model is appropriate for model (A) and the values assumed for success probabilities in the
simulations.
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Conclusions and future work
In the framework of a probabilistic analysis of adaptive experimental design, this thesis
focuses on the description and analysis of a new response-adaptive design: the Klein
urn design. On the one hand, the asymptotic structure of the Klein urn design has been
analyzed and a parametric inferential study has been developed. The behavior of the Klein
urn design is asymptotically very similar to the behavior of the drop-the-loser design, which
is considered as a very competitive design in the literature. On the other hand, a thorough
study of the exact properties of the Klein urn design can be made for any sample size n
due to its probabilistic structure, based on Markov Chains. This is an advantage with
respect to the drop-the-loser design for which exact properties are not well studied.
Along with the parametric inference, randomization based inference has also been
studied for response-adaptive designs. The use of adaptive designs complicates the ran-
domization based inference process, because all the allocation arrangements are not equally
probable as in complete randomization, but these difficulties have been overcome and an
exact and asymptotic study has been completed. Recurrence relations have been used
to obtain the exact distributions of some statistics and the p-values associated to these
statistics. In addition central limit theorems for these test statistics have been proven.
This asymptotic result gives an alternative to the use of Monte Carlo approximation which
is more familiar in clinical research practice.
The behavior of the Klein urn design has been analyzed when covariates are included in
the design, extending the spectrum of its applicability. Ad-hoc estimators under a stratified
design and also the maximum quasi likelihood estimators of the generalized linear model
have been studied and their properties have been obtained. Finally, a simulation study
has been carried out comparing randomization based inference and inference based on
generalized linear models. It has been concluded that the RBI has not a worse behavior
than inference based on GLM, thereby it becomes a viable alternative, with the advantage
that is free of model specifications.
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Some results can be extended or generalized. In Chapter 2 there is a conjecture about
the limit of the maximum eigenvalue, which is related to a measurement of the accidental
bias. In Theorem 4.2.1 milder conditions on the coefficients could be of interest. A study
of the speed of convergence would complete the different limit laws obtained. Dichotomous
responses have been arisen in this thesis, so a generalization to other kind of responses
would be of interest, specially in the algorithm for obtaining the exact distribution of the
test statistic Sn. It would also be of interest a randomization based inferential study for
other statistics as, for instance, the pooled statistic presented in Remark 5.1.1. and the
inference for different link functions when generalized linear models are used.
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Conclusiones y trabajo futuro
Esta tesis se ha centrado en la presentacio´n y estudio del disen˜o de urna de Klein. Por
un lado, se ha analizado su estructura asinto´tica y se ha hecho un estudio inferencial
parame´trico, siendo el comportamiento asinto´tico del disen˜o de urna de Klein muy parecido
al disen˜o drop-the-loser, reconocido en la literatura por sus buenas propiedades. Por
otro lado, por su estructura probabil´ıstica basada en cadenas de Markov, se tiene un
conocimiento amplio sobre sus propiedades exactas, para cualquier taman˜o de muestra,
mejor que el disponible para el disen˜o DTL.
Adema´s de la inferencia parame´trica, se ha profundizado en la inferencia no parame´trica
basada en la aleatorizacio´n. La utilizacio´n de disen˜os adaptativos presenta algunas difi-
cultades para realizar la inferencia basada en la aleatorizacio´n: en general, no todas las
configuraciones o reordenaciones de tratamientos son factibles, y las configuraciones posi-
bles pueden tener distintas probabilidades. Se han resuelto estas dificultades y se han
obtenido resultados exactos y asinto´ticos. Por una parte, se han obtenido resultados de
recurrencia que permiten calcular la distribucio´n exacta de diversos estad´ısticos y de los
p-valores para los contrastes asociados a esos estad´ısticos. Estos resultados son aplicables
para taman˜os muestrales pequen˜os o moderados. Por otra parte, se han obtenido teoremas
centrales del l´ımite para algunos de estos estad´ısticos. Estos resultados proporcionan una
alternativa sencilla a la utilizacio´n de te´cnicas de aproximacio´n de Monte Carlo. Adema´s,
esta aproximacio´n por una distribucio´n normal es ma´s cercana a la pra´ctica habitual de
los investigadores cl´ınicos.
Finalmente, tambie´n se ha analizado el comportamiento del disen˜o de urna de Klein
ante la presencia de covariables, ampliando el espectro de su aplicabilidad. Se han de-
mostrado las propiedades de estimadores ad-hoc en el caso estratificado y de los esti-
madores de ma´xima cuasi-verosimilitud para el modelo lineal generalizado, haciendo posi-
ble un estudio de inferencia tambie´n en este caso. Se ha comparado la inferencia basada
en la aleatorizacio´n y la basada en estimadores de los modelos lineales generalizados, y se
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ha concluido que a pesar de requerir menos hipo´tesis, la inferencia basada en la aleator-
izacio´n no tiene un comportamiento peor, con lo que se convierte en una alternativa va´lida
y factible, con la ventaja de estar libre de especificaciones.
Algunos resultados son ampliables o generalizables. En el cap´ıtulo 2 se ha enunciado
una conjetura acerca del comportamiento asinto´tico de un valor propio ma´ximo, rela-
cionado con el ca´lculo del sesgo accidental. En el Teorema 4.2.1, las condiciones sobre los
coeficientes son exigentes, as´ı que una relajacio´n de e´stas ser´ıa de intere´s. En los diferentes
teoremas l´ımite demostrados, ser´ıa interesante tambie´n hacer un estudio de velocidades
de convergencia. En la tesis se han considerado respuestas dicoto´micas. La generalizacio´n
a otro tipo de respuestas es un campo abierto, siendo de especial intere´s el ca´lculo del
estad´ıstico Sn para cualquier tipo de respuesta. En el cap´ıtulo 5, ser´ıa interesante un estu-
dio inferencial basado en la aleatorizacio´n para el estad´ıstico ponderado del Remark 5.1.1.
y tambie´n se podr´ıan considerar diferentes funciones de enlace en los modelos lineales
generalizados, asociados a diferentes tipos de respuestas.
La realizacio´n de esta tesis ha sido posible gracias a una beca predoctoral del Gobierno
de Navarra.
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